<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment and prognosis of neuroblastoma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment and prognosis of neuroblastoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment and prognosis of neuroblastoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jason M Shohet, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jed G Nuchtern, MD, FACS, FAAP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer H Foster, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julie R Park, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 25, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The term neuroblastoma is commonly used to refer to a spectrum of neuroblastic tumors (including neuroblastomas, ganglioneuroblastomas, and ganglioneuromas) that arise from primitive sympathetic ganglion cells, and like paraganglioma and pheochromocytomas, have the capacity to synthesize and secrete catecholamines. (See  <a class="medical medical_review" href="/z/d/html/130.html" rel="external">"Clinical presentation and diagnosis of pheochromocytoma"</a> and  <a class="medical medical_review" href="/z/d/html/5231.html" rel="external">"Paragangliomas: Epidemiology, clinical presentation, diagnosis, and histology"</a>.)</p><p>Neuroblastomas, which account for 97 percent of all neuroblastic tumors, are clinically heterogeneous, varying in location, histopathologic appearance, and biologic characteristics [<a href="#rid1">1</a>]. They are most remarkable for their broad spectrum of clinical behavior, which can range from spontaneous regression to maturation to a benign ganglioneuroma, or aggressive disease with metastatic dissemination leading to death [<a href="#rid2">2</a>]. Clinical diversity correlates closely with numerous clinical and biological factors, although its molecular basis remains largely unknown. For example, most infants with disseminated disease have a favorable outcome after treatment with chemotherapy and surgery, while about half of children over the age of 18 months who have advanced neuroblastoma die from progressive disease despite intensive multimodality therapy.</p><p>The treatment and prognosis of neuroblastoma will be reviewed here and is meant to be an overview for the general oncologist. Due to the rarity of this disease, patients should be managed in a setting where appropriate expertise in the treatment of neuroblastoma is available.</p><p>The epidemiology, clinical presentation, and diagnosis of neuroblastoma are presented separately, as is a discussion of neuroblastomas arising in the olfactory epithelium. (See  <a class="medical medical_review" href="/z/d/html/5204.html" rel="external">"Epidemiology, pathogenesis, and pathology of neuroblastoma"</a> and  <a class="medical medical_review" href="/z/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma"</a> and  <a class="medical medical_review" href="/z/d/html/5183.html" rel="external">"Olfactory neuroblastoma (esthesioneuroblastoma)"</a>.)</p><p class="headingAnchor" id="H1907725814"><span class="h1">STAGING SYSTEM</span><span class="headingEndMark"> — </span>Two staging systems exist for patients with neuroblastoma. This topic is organized using a risk-stratified approach that incorporates the International Neuroblastoma Risk Group Staging (INRGSS)  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a>), along with molecular, pathologic, and other clinical characteristics. However, certain sections in this topic define patient risk groups or include studies that use the International Neuroblastoma Staging System (INSS)  (<a class="graphic graphic_table graphicRef73974" href="/z/d/graphic/73974.html" rel="external">table 2</a>), which has been noted where relevant. </p><p>Further details of the available staging systems are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Neuroblastoma Staging System</strong> –<strong> </strong>The INSS was adopted in the 1990s and was the first uniform staging system  (<a class="graphic graphic_table graphicRef73974" href="/z/d/graphic/73974.html" rel="external">table 2</a>) [<a href="#rid3">3</a>]. Tumor stage in this system is defined according to resectability and spread to lymph nodes or distant sites.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>International Neuroblastoma Risk Group Staging System</strong> –<strong> </strong>In 2009, a revised staging system, the INRGSS, was developed, which incorporated pretreatment imaging parameters rather than findings at resection  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a>) [<a href="#rid4">4,5</a>]. Data suggest that this revised staging system offers improved insights into which patients require intensive treatment  (<a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a>) [<a href="#rid6">6</a>]. All international cooperative groups, including the Children's Oncology Group (COG), validate and incorporate this staging system into their prospective research.</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>Neuroblastomas are diverse in their clinical behavior. Certain factors influence the biologic behavior of these tumors and are helpful in predicting outcome; some are patient-related (eg, age at the time of diagnosis), while the majority are tumor-related (disease stage, tumor histology, molecular and cytogenetic features).</p><p class="headingAnchor" id="H1037008919"><span class="h2">Stage</span><span class="headingEndMark"> — </span>The extent of metastatic spread at presentation is the most important factor in determining outcome for patients with neuroblastoma [<a href="#rid4">4,7-9</a>]. Although regional spread to lymph nodes attached or adjacent to the primary tumor does not significantly affect outcome, distant metastatic disease (eg, bone marrow involvement) confers a much worse prognosis. (See <a class="local">'Staging system'</a> above.)</p><p>Disease stage at diagnosis is to some extent influenced by age; a greater proportion of patients diagnosed after one year of age have stage 3 or 4 disease compared with those who present earlier (80 versus 41 percent) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H4036132583"><span class="h2">Age</span><span class="headingEndMark"> — </span>The age at diagnosis is an important prognostic factor in children with neuroblastoma [<a href="#rid10">10-13</a>]. However, predicting outcomes based on age can be complicated by other factors that also impact response to therapy, such as multiple genetic factors and heterogenous pathophysiology [<a href="#rid14">14</a>]. In general, the younger the age at diagnosis, the better the survival rate (with the exception of newborns) [<a href="#rid13">13,15,16</a>]. (See <a class="local">'Newborns'</a> below.)</p><p class="headingAnchor" id="H3384354065"><span class="h3">Survival based on age</span><span class="headingEndMark"> — </span>Based on data from the Surveillance, Epidemiology and End Results (SEER) database, overall survival based on age are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>The five-year survival rate for all children with neuroblastoma is approximately 80 percent [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Young children beyond the newborn stage appear to have the best prognosis, particularly until 18 months [<a href="#rid13">13,18</a>]. This age has been incorporated into the treatment regimens as well as the proposed International Neuroblastoma Risk Group Staging System (INRGSS) [<a href="#rid4">4</a>]. The significantly better outcome of disseminated disease in infants (children less than one year old [<a href="#rid19">19</a>]) compared with other age groups is reflected in the special 4S category of disease stage  (<a class="graphic graphic_table graphicRef73974" href="/z/d/graphic/73974.html" rel="external">table 2</a>), which applies only to infants. (See <a class="local">'Stage MS (4S) disease'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children between 18 months and 5 years of age with high-risk disease, event-free survival (EFS) is approximately 39 percent and overall survival (OS) is between 40 and 50 percent [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients diagnosed between ages 5 and 10 years, OS is approximately 49 percent. For patients diagnosed over age 10 years, OS is 46 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although adolescent neuroblastoma appears to have a more indolent phenotype, these patients experience a higher number of late relapses and deaths [<a href="#rid21">21</a>]. Even low-stage, histologically favorable, or less aggressive-appearing neuroblastomas fare worse as children get older [<a href="#rid13">13,22</a>]. (See <a class="local">'Histology'</a> below.)</p><p></p><p class="headingAnchor" id="H69857926"><span class="h3">Newborns</span><span class="headingEndMark"> — </span>Neonates (ie, newborns younger than two months of age) who have INRGSS stage MS (ie, International Neuroblastoma Staging System [INSS] stage 4S) neuroblastoma typically present with aggressive disease and are an exception to the general rule that younger age is associated with better outcome. (See <a class="local">'Survival based on age'</a> above.)</p><p>Among this small subset of patients, neuroblastoma metastases in the liver can grow rapidly, with high resulting morbidity and mortality. In addition to liver dysfunction with coagulopathy, these metastases can cause hepatomegaly with subsequent pulmonary compromise, abdominal compartment syndrome, and/or renal failure [<a href="#rid13">13,23,24</a>]. As an example, the Children's Oncology Group (COG) study ANBL0531 included 49 infants with stage MS (4S) neuroblastoma who required treatment for symptoms, 25 of whom were diagnosed before two months of age [<a href="#rid25">25</a>]. Four of these 25 died due to complications of liver metastases, compared with one of the 24 infants over age two months. For this reason, the COG now recommends urgent initiation of chemotherapy in young infants with stage MS (4S) neuroblastoma with evolving hepatomegaly, using a similar chemotherapy approach to those with intermediate-risk disease. (See <a class="local">'Chemotherapy'</a> below.)</p><p>By contrast, newborns who have limited adrenal disease (typically diagnosed by prenatal ultrasound) have a favorable prognosis and frequently do not need treatment. (See <a class="local">'Newborns with small, asymptomatic adrenal masses'</a> below.)</p><p class="headingAnchor" id="H4"><span class="h2">Stage MS (4S) disease</span><span class="headingEndMark"> — </span>Stage 4S neuroblastoma per the INSS criteria describes infants below one year of age  (<a class="graphic graphic_table graphicRef73974" href="/z/d/graphic/73974.html" rel="external">table 2</a>) who have resectable primary tumors (stage 1 or 2) and metastases that are limited to the liver, skin, and bone marrow (&lt;10 percent); infants with metastases to cortical bone are excluded from this category. The INRGSS has modified the definition of 4S (now called MS) to include patients up to 18 months of age and those with regional spread of primary tumor  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a>). The prognostic influence of younger age at diagnosis is discussed in detail separately. (See <a class="local">'Age'</a> above.)</p><p>The MS (or 4S) category is an exception to the typically dismal prognosis for children with widespread metastases from neuroblastoma [<a href="#rid18">18</a>]. Overall survival for infants in this category is over 90 percent [<a href="#rid23">23</a>]. One contributing factor is that the tumor cells in infants with stage 4S (MS) disease have the capacity to undergo spontaneous regression [<a href="#rid26">26,27</a>].</p><p>However, like all stages of neuroblastomas, the tumors that make up stage MS (4S) disease are heterogeneous. For example, newborns less than two months with MS (4S) disease may present with more aggressive disease. Thus, patients require risk-adjusted treatment protocols [<a href="#rid24">24</a>]. (See <a class="local">'Newborns'</a> above and <a class="local">'Low-risk disease'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h2">Histology</span><span class="headingEndMark"> — </span>Although the importance of histology as an independent prognostic factor has been somewhat superseded by molecular markers in the INRGSS risk classification, it is still important for certain higher stage tumors in older children [<a href="#rid4">4,28</a>]. (See <a class="local">'Cytogenetics and molecular genetics'</a> below.)</p><p>The balance between neural-type cells and Schwann-type (Schwannian) cells helps to categorize the tumor as neuroblastoma, ganglioneuroblastoma, or ganglioneuroma. In turn, neuroblastomas can have varying degrees of differentiation (undifferentiated, poorly differentiated, or differentiating). These histologic subtypes are described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5204.html" rel="external">"Epidemiology, pathogenesis, and pathology of neuroblastoma", section on 'Pathology'</a>.)</p><p>The International Neuroblastoma Pathology Classification (INPC) system, established in 1999 [<a href="#rid28">28-31</a>], relates the histopathologic features of the tumor, other biologic variables, and patient age to clinical behavior [<a href="#rid32">32</a>]. Tumors are classified as favorable or unfavorable based upon the degree of neuroblast differentiation, Schwannian stroma content, the frequency of cell division (the mitosis-karyorrhexis index [MKI]), and age at diagnosis. The INPC is a modification of a previous risk classification scheme, the Shimada system [<a href="#rid32">32</a>].</p><p>In one validation study of the INPC system, five-year EFS was more than three times greater among children with favorable histology tumors compared with unfavorable histology tumors (90 versus 27 percent) [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Cytogenetics and molecular genetics</span><span class="headingEndMark"> — </span>Certain molecular and cytogenetic tumor characteristics correlate with prognosis. These include, but are not limited to, <em>MYCN</em> (<em>N-myc</em>) amplification, DNA content (ploidy), and gain or loss of whole or partial chromosomes (ie, segmental chromosomal aberrations [SCAs]). The importance of these features is reflected in their inclusion as prognostic factors in determining risk assignment for treatment  (<a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a>) [<a href="#rid33">33</a>]. Additional characteristics which may influence treatment decisions include <em>ALK</em> aberrations [<a href="#rid34">34,35</a>] and telomere maintenance mechanisms [<a href="#rid36">36,37</a>]. (See  <a class="medical medical_review" href="/z/d/html/5204.html" rel="external">"Epidemiology, pathogenesis, and pathology of neuroblastoma", section on 'Molecular abnormalities (prognostic impact)'</a> and <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Improvements in outcome for children with neuroblastoma have been the result of cooperative group, multicenter clinical trials, which have integrated combined modality approaches with an understanding of the prognostic factors affecting outcome. Patients should be managed in a setting where appropriate expertise in the treatment of neuroblastoma is available. (See <a class="local">'Risk stratification'</a> below.)</p><p class="headingAnchor" id="H2455888061"><span class="h2">Risk stratification</span><span class="headingEndMark"> — </span>The treatment of neuroblastoma is determined based on risk categories  (<a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a>). Patients are classified into low-, intermediate-, and high-risk categories based on the following characteristics at the time of diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage of the disease</p><p class="bulletIndent1"><span class="glyph">●</span>Patient age</p><p class="bulletIndent1"><span class="glyph">●</span>Extent of INRGSS L1 disease resection  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a>) </p><p class="bulletIndent1"><span class="glyph">●</span>Presence or absence of amplification of the <em>MYCN</em> oncogene</p><p class="bulletIndent1"><span class="glyph">●</span>Quantitative DNA content of the tumor (DNA index or ploidy)</p><p class="bulletIndent1"><span class="glyph">●</span>Histologic appearance of the tumor</p><p class="bulletIndent1"><span class="glyph">●</span>Segmental chromosomal aberrations (eg, loss of heterozygosity [LOH] 11q) [<a href="#rid38">38</a>]</p><p></p><p>Risk categories evolve as newer staging systems are adopted and further knowledge is acquired about molecular and genetic determinants of tumor behavior and prognosis. As an example, an updated Children’s Oncology Group (COG) risk classification scheme incorporating the International Neuroblastoma Risk Group Staging System (INRGSS) is used to characterize all tumors in ongoing and future COG studies, along with molecular, pathologic, and other clinical characteristics listed above  (<a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a>). [<a href="#rid33">33</a>] A previous COG risk classification schema  (<a class="graphic graphic_table graphicRef68159" href="/z/d/graphic/68159.html" rel="external">table 3</a>) was based on the International Neuroblastoma Staging System (INSS)  (<a class="graphic graphic_table graphicRef73974" href="/z/d/graphic/73974.html" rel="external">table 2</a>). (See <a class="local">'Staging system'</a> above.)</p><p class="headingAnchor" id="H11"><span class="h2">Low-risk disease</span><span class="headingEndMark"> — </span>Low-risk disease is defined according to the COG risk categorization schema  (<a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef68159" href="/z/d/graphic/68159.html" rel="external">table 3</a>). Patients in the low-risk category generally have localized tumors without unfavorable characteristics. This includes low-stage disease (eg, INSS stage 1, 2A, or 2B,  (<a class="graphic graphic_table graphicRef73974" href="/z/d/graphic/73974.html" rel="external">table 2</a>); or INRGSS stage L1  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a>)), and tumors are <em>MYCN</em> non-amplified, hyperdiploid, and have favorable histology. (See <a class="local">'Risk stratification'</a> above.)</p><p>In general, tumor outcomes for children with low-risk neuroblastoma are excellent. Patients who relapse generally can be salvaged with further surgery or chemotherapy.</p><p class="headingAnchor" id="H2413269484"><span class="h3">Surgery (preferred for most patients with low-risk disease)</span><span class="headingEndMark"> — </span>Surgery is indicated in most patients with low-risk tumors beyond infancy (eg, children older than one year with INSS stage 1 or 2 disease [L1]) [<a href="#rid39">39-43</a>]. Patients treated with surgery typically do not require adjuvant chemotherapy. Although surgery has been the preferred option for patients with low-risk disease, a subgroup of much younger patients with small tumors (eg, INRGSS stage L1 disease) are typically managed with observation alone. (See <a class="local">'Subgroups that can be managed with observation alone'</a> below.)</p><p>Two- to five-year event-free survival (EFS) rates with surgery alone are greater than 93 percent for children with stage 1 disease; because recurrences can be successfully managed with further surgery or chemotherapy, five-year overall survival (OS) rates are 95 percent [<a href="#rid39">39,40,44</a>].</p><p>For most children with asymptomatic stage 2A or 2B disease, the outlook after surgery alone is also excellent. In contrast, children with symptomatic stage 2A or 2B disease are treated similarly to those with intermediate-risk disease and offered initial chemotherapy; among this rare group of patients, surgery is reserved for those who do not respond to chemotherapy. (See <a class="local">'Intermediate-risk disease'</a> below.)</p><p>Chemotherapy was a component of early treatment regimens but has gradually been removed over successive clinical trials without detriment to patient outcomes [<a href="#rid39">39,40</a>]. This was illustrated by a nonrandomized COG clinical trial (P9641) for 915 infants and children INSS stage 2A and 2B disease who underwent surgical resection followed by either observation or chemotherapy [<a href="#rid44">44</a>]. Chemotherapy was reserved for patients with or at risk for symptomatic disease, with less than 50 percent tumor resection at diagnosis, or with unresectable progressive disease after surgery alone. Five-year OS and EFS were similar in patients treated with surgery alone compared with those treated with surgery and chemotherapy (OS 97 versus 98 percent; EFS 89 versus 91 percent).</p><p class="headingAnchor" id="H198447920"><span class="h3">Subgroups that can be managed with observation alone</span></p><p class="headingAnchor" id="H433137774"><span class="h4">Newborns with small, asymptomatic adrenal masses</span><span class="headingEndMark"> — </span>For infants &lt;6 months of age with small (ie, tumor diameter ≤3.1 cm for solid masses and ≤5.0 cm for cystic masses), asymptomatic INRGSS stage L1  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a>) adrenal masses, we recommend expectant observation, forgoing diagnostic surgical biopsy, rather than other interventions (eg, surgery or chemotherapy) at initial diagnosis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observation schedule </strong>– For these patients, we recommend observation using serial ultrasounds of the adrenal mass with monitoring of urine catecholamines, vanillylmandelic acid (VMA) and homovanillic acid (HVA). These tests may be performed every three weeks for two visits, then every six weeks for two visits, then every 12 weeks for two visits, then every 24 weeks for two visits. If there is increase in tumor size, we recommend returning evaluation frequency to every three weeks. Patients should undergo surgical biopsy and possible resection if there is tumor progression [<a href="#rid45">45</a>]; in this subset of patients, if complete surgical resection can be safely performed, then chemotherapy can be avoided.</p><p></p><p>With advances in prenatal imaging, adrenal masses may be detected in infants before birth. Similar masses may be incidentally identified in neonates during imaging performed for other indications. These patients represent a favorable cohort [<a href="#rid46">46-48</a>]. While surgery is curative, it can be associated with significant morbidity and mortality, such as tumoral rupture, bleeding, infection, and injury to the great vessels, nerves, or kidneys [<a href="#rid49">49,50</a>]. A number of studies have indicated that expectant observation is safe in newborns with localized neuroblastoma, and that many of these tumors spontaneously regress [<a href="#rid46">46-48,51-54</a>].</p><p>In a COG prospective study (ANBL00P2) of 87 infants younger than six months with small adrenal masses, 83 of the 87 were initially observed. Spontaneous reduction in tumor volume was noted in two-thirds of patients, including 27 patients with no residual mass by the end of follow-up [<a href="#rid54">54</a>]. Surgery was avoided in 81 percent of patients with a median follow-up of 3.2 years, and three-year OS was 100 percent. Among the patients who underwent resection, the majority had confirmed stage I disease. A diagnosis other than neuroblastoma was observed in seven patients at the time of surgery; alternative diagnoses included extralobar pulmonary sequestration, adrenal cortical neoplasm, and hematoma.</p><p class="headingAnchor" id="H2490905068"><span class="h4">Infants with stage MS (4S) disease without hepatomegaly</span><span class="headingEndMark"> — </span>Infants with asymptomatic MS (stage 4S) disease without hepatomegaly and with tumors that are <em>MYCN</em> non-amplified, hyperdiploid, and have favorable histology may also be initially observed. In these patients, a high rate of spontaneous regression is seen (up to 70 percent) [<a href="#rid27">27</a>], and treatment can thus be deferred [<a href="#rid23">23,24</a>]. These patients require a tissue biopsy to exclude <em>MYCN</em> amplification and other tumor characteristics that would place them in an intermediate- or high-risk group. This biopsy can be from the primary tumor, bone marrow, or other metastatic sites.</p><p>We offer a similar observation schedule to that for newborns with small adrenal masses, using ultrasound images of liver and primary mass. This subset of patients with 4S (MS) disease may benefit from a longer period of observation (ie, two to three years from the date of diagnosis). (See <a class="local">'Newborns with small, asymptomatic adrenal masses'</a> above.)</p><p>Patients with tumor growth and/or progressive disease-related symptoms (eg, those at risk for developing neurologic compromise due to spinal cord compression) should be referred for chemotherapy and possible surgery, per the approach for those with intermediate-risk disease. (See <a class="local">'Chemotherapy'</a> below.)</p><p>The COG study ANBL1232 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02176967&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzh35RvrgLNrXQnXVeh%2FjIker6EM7oTt2xeUTFDDg3hkQ%3D%3D&amp;TOPIC_ID=5203" target="_blank">NCT02176967</a>) seeks to further define criteria for patients up to age 18 months with INGRSS stage MS neuroblastoma  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a>) who may be able to delay or avoid chemotherapy versus those who require urgent treatment due to risk for poor outcome [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H974579"><span class="h4">Infants less than one year old with localized disease &lt;5 cm</span><span class="headingEndMark"> — </span>Some experts offer observation to select children less than one year of age with asymptomatic, localized, biopsy-proven neuroblastoma (ie, INSS stage 1, 2, or 3  (<a class="graphic graphic_table graphicRef73974" href="/z/d/graphic/73974.html" rel="external">table 2</a>), INRGSS stage L1 or L2  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a>)) with both favorable histology and genomics (eg, without <em>MYCN</em> amplification or segmental chromosomal aberrations). These patients may be observed with close monitoring of imaging and tumor markers, such as urine catecholamines. (See <a class="local">'Histology'</a> above and <a class="local">'Cytogenetics and molecular genetics'</a> above.)</p><p>However, this observational strategy is investigational, and other experts may alternatively offer standard treatment approaches (eg, surgery or chemotherapy) in these patients. The COG study ANBL1232 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT02176967&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzh35RvrgLNrXQnXVeh%2FjIker6EM7oTt2xeUTFDDg3hkQ%3D%3D&amp;TOPIC_ID=5203" target="_blank">NCT02176967</a>) seeks to expand criteria for patients who may be followed with observation only or after initial biopsy [<a href="#rid55">55</a>].</p><p>Data supporting observation for these patients are as follows:</p><p>In a prospective, nonrandomized multicenter study, 93 of 340 infants (27 percent) with localized neuroblastoma and without <em>MYCN</em> amplification were observed without either primary resection of gross residual tumor or chemotherapy following the initial diagnosis [<a href="#rid56">56</a>]. The following findings were noted in this study:</p><p class="bulletIndent1"><span class="glyph">●</span>At a median follow-up of 58 months, spontaneous remissions were observed in 44 of 93 patients (47 percent), including 17 complete responses. 35 patients (38 percent) had evidence of local progression or stage 4S, four patients (4 percent) had progression to stage 4, and 10 patients (11 percent) had no change in tumor size.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgery and/or chemotherapy were used to salvage those children who had evidence of progression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor regression occurred over an extended time frame, with median times to first evidence and complete regression of 3.3 and 10 months, respectively. The first evidence of regression did not appear until after age one year in 15 of the 44 cases (34 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The three-year OS and metastasis-free survival rates for those initially managed with observation were 99 and 94 percent, not significantly different from those initially managed with surgery or chemotherapy.</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Intermediate-risk disease</span><span class="headingEndMark"> — </span>According to the COG risk classification schema, intermediate-risk disease includes patients who do not meet criteria for either low-risk or high-risk disease  (<a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H19"><span class="h3">Chemotherapy</span><span class="headingEndMark"> — </span>For children with intermediate-risk neuroblastoma, we suggest moderately intensive multiagent neoadjuvant chemotherapy (eg, with <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, a platinum drug, and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>) with or without surgical resection, rather than surgery alone [<a href="#rid12">12,57-59</a>]. The goal of treatment is to deliver a sufficient duration of chemotherapy (with or without subsequent surgery) to achieve at least a partial response (at least 50 percent reduction of soft tissue masses) and resolution of metastatic disease [<a href="#rid59">59</a>].</p><p>The duration of chemotherapy is typically 6 to 24 weeks and is optimized based on specific tumor histologic and biologic characteristics. As an example, patients who receive longer durations of chemotherapy typically have tumors with unfavorable histology; diploidy (ie, DNA index = 1); or segmental chromosomal aberrations (ie, LOH of 1p or unbalanced LOH of 11q).</p><p>The rationale for combined-modality approach to treatment comes from a report from the Children's Cancer Group (CCG) in which children with intermediate-stage disease received five courses of chemotherapy, followed by surgery, another course of chemotherapy, radiation therapy (RT) for gross residual disease, and four more courses of chemotherapy [<a href="#rid12">12</a>]. The four-year EFS for patients with favorable biology was 100 percent, while for infants with at least one unfavorable biologic feature, EFS was 90 percent.</p><p>As a result of treatment successes with this regimen, subsequent clinical investigations have decreased chemotherapy intensity and aggressiveness of local control measures, as illustrated by the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In a COG trial (A3961) for intermediate-risk neuroblastoma, four cycles of chemotherapy were given for tumors with favorable biologic features, and eight cycles were given for tumors with unfavorable features [<a href="#rid57">57</a>]. Children treated in this way did just as well as in previous studies using more cycles of chemotherapy, with three-year EFS and OS of 88 and 96 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study performed by the Society of Pediatric Oncology European Neuroblastoma Network (SIOPEN), infants with unresectable tumors received low doses of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> until tumors were resectable. This study of 180 infants included 84 children with stage 3 tumors. Again, the reduction in chemotherapy was not detrimental to five-year EFS or OS, which remained 90 and 99 percent, respectively [<a href="#rid58">58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The COG trial for intermediate-risk neuroblastoma (ANBL0531) demonstrated excellent survival outcomes with omitting cycles of neoadjuvant chemotherapy and/or as surgery [<a href="#rid59">59</a>]. In this single arm phase III trial, 404 patients were stratified and treated based on patient age, stage, genetic, and histologic features. Patients were treated with either two, four, or eight cycles of neoadjuvant chemotherapy. Longer durations of chemotherapy were assigned to patients with unfavorable histology, diploidy (ie, DNA index = 1), or segmental chromosomal aberrations (eg, LOH of 1p or unbalanced LOH of 11q). Patients then underwent subsequent surgery or additional chemotherapy based on tumor response. Surgery was omitted in those with partial responses or better, which comprised a majority of patients. Patients who did not achieve the defined treatment endpoints received additional chemotherapy. This study included some patients whose disease would previously have been considered low or high risk, which limits the ability to compare the results to other studies evaluating this approach.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For the 404 patients enrolled, three-year EFS was 83 percent and OS was 95 percent. Those with localized tumors (stages 2 and 3 patients) had a three-year EFS of 88 percent and OS of 100 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants with stage 4S disease had a three-year OS of 82 percent, largely due to early death from hepatomegaly.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infants with stage 4 disease had a three-year EFS and OS of 78 and 91 percent, respectively. Within this group though, those with unfavorable tumor biology fared much worse than those with favorable biology (three-year EFS 67 versus 87 percent), indicating that different treatment strategies may be needed for these patients [<a href="#rid59">59</a>]. (See <a class="local">'Prognostic factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Three-year EFS for those treated with two, four, or eight cycles of chemotherapy was 87, 87, and 80 percent, respectively; three-year OS was 99, 94, and 87 percent.</p><p></p><p class="headingAnchor" id="H3316981421"><span class="h3">Indications for surgery</span><span class="headingEndMark"> — </span>For intermediate-risk neuroblastoma, initial aggressive surgical resection is discouraged unless the tumor can be removed without threat to adjacent vital structures. Preoperative chemotherapy can decrease tumor size and increase ease of resection, or even eliminate the need for resection [<a href="#rid59">59</a>]. Surgery is indicated in patients who do not achieve a partial response (PR) or very good partial response (VGPR) with initial chemotherapy, whichever response is mandated based on the patient's overall risk stratification. For such patients, the decision to proceed with surgery rather than additional chemotherapy is based on the likelihood that resection can achieve the desired response without significant risk to vital structures (eg, kidneys, nerves, or vascular structures). Regardless, all patients should undergo initial surgical biopsy to obtain a diagnosis and discern histologic and genomic features that inform duration of initial chemotherapy [<a href="#rid57">57,60-62</a>]. (See  <a class="medical medical_review" href="/z/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma", section on 'Biopsy'</a>.)</p><p>The feasibility of complete resection is determined by tumor location and mobility, relationship to major nerves and blood vessels, the presence of distant metastases, and patient age. Sacrifice of vital organs to achieve a complete resection of large primary tumors at the time of diagnosis should be avoided. Surgery should be delayed in circumstances when less than 50 percent of the tumor can be safely removed, and chemotherapy should be administered after biopsy, to either achieve a PR or VGPR (based on specific risk stratification) or to allow for a safer surgical procedure to achieve the goal tumor response.</p><p>The ultimate extent of surgical resection necessary for optimal outcomes has been debated [<a href="#rid57">57,60-62</a>]. Data from the COG study ANBL0531 suggest that among patients with localized favorable histology tumors receiving chemotherapy with or without surgery, good EFS and OS can be achieved with an end-of-therapy goal of partial response, even if surgical resection is omitted [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Avoidance of radiation therapy</span><span class="headingEndMark"> — </span>Cooperative groups avoid radiation therapy (RT) for patients with intermediate-risk disease and recommend it only in the setting of emergent life- or organ-threatening complications or disease progression despite surgery and chemotherapy [<a href="#rid2">2,57,59</a>].</p><p class="headingAnchor" id="H21"><span class="h2">High-risk disease</span><span class="headingEndMark"> — </span>Patients most commonly at the highest risk for disease progression and mortality are generally those who are older than 18 months of age and have either disseminated disease or localized disease with unfavorable markers such as <em>MYCN</em> amplification  (<a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef68159" href="/z/d/graphic/68159.html" rel="external">table 3</a>) regardless of age. (See <a class="local">'Risk stratification'</a> above.)</p><p>Multiple genetic and biologic factors contribute to the risk of treatment failure, and tailoring therapy to reflect these factors is an ongoing challenge [<a href="#rid14">14,34,63</a>]. Despite aggressive multimodality therapy, current survival rates remain unacceptably low (approximately 50 percent) [<a href="#rid9">9,64</a>], and the improved outcomes have come at a cost of significant early and late toxicity. (See <a class="local">'Prognosis'</a> below.)</p><p>Improved survival outcomes have been achieved using an aggressive multimodality approach that includes chemotherapy, surgical resection, hematopoietic stem-cell transplantation, RT, and immunotherapy [<a href="#rid65">65,66</a>]. Prior to instituting this approach, the long-term survival probability for children with high-risk disease was less than 15 percent. Data from randomized trials have consistently demonstrated improved EFS in patients who received myeloablative chemotherapy with stem cell rescue [<a href="#rid67">67-69</a>], and some of these studies demonstrated an improvement in OS in certain groups of patients [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H2054801221"><span class="h3">Components of treatment</span><span class="headingEndMark"> — </span>The following briefly summarizes the general components of treatment for high-risk disease, which includes induction therapy, local control (with surgical resection and RT), consolidation with tandem autologous hematopoietic stem cell transplantation, and maintenance therapy. Specific treatment details are beyond the scope of this review and treatment should be administered under the guidance of a multidisciplinary team of pediatric oncologists, surgeons, and radiation oncologists with expertise in the treatment of neuroblastoma. Additionally, such treatment protocols may be individualized based on the institution.</p><p class="headingAnchor" id="H963309966"><span class="h3">Induction</span></p><p class="headingAnchor" id="H1573616923"><span class="h4">Chemotherapy</span><span class="headingEndMark"> — </span>Since patients typically present with unresectable disease, the rationale for induction chemotherapy is to reduce primary and metastatic tumor burden and allow attempts at local control. The choice of induction regimen is typically dependent upon institution and location. While observational and randomized studies have compared the impact of various available induction regimens on survival and long-term toxicity, further data are necessary to determine the optimal regimen [<a href="#rid70">70-72</a>]. In the United States, the most widely used induction regimen includes five cycles of intensive chemotherapy with a combination of agents (<a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10007" href="/z/d/drug information/10007.html" rel="external">topotecan</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>) [<a href="#rid73">73-75</a>]. Rapid COJEC (a combination of cisplatin [C], vincristine [O], <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> [J], etoposide [E], and cyclophosphamide [C]) is used in Europe [<a href="#rid76">76,77</a>].</p><p class="headingAnchor" id="H3576681203"><span class="h4">Investigational induction therapies</span><span class="headingEndMark"> — </span>For subsets of high-risk patients, the COG phase III clinical trial ANBL1531 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03126916&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSz9wsRalc77CFv9OFo%2BGIinZCvMlvWKCBaUIH5YDOsrAw%3D%3D&amp;TOPIC_ID=5203" target="_blank">NCT03126916</a>) is also evaluating the safety and impact on EFS of incorporating ALK inhibitors and therapeutic I<sup>131</sup> meta-iodobenzylguanidine (MIBG) therapy with induction chemotherapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>ALK inhibition </strong>– In patients with ALK-activating mutations enrolled in COG ANBL1531, an ALK inhibitor is administered after the first cycle of induction chemotherapy until consolidation, and then restarted after the completion of immunotherapy. Of note, close monitoring for respiratory changes is advised when <a class="drug drug_general" data-topicid="119539" href="/z/d/drug information/119539.html" rel="external">lorlatinib</a> and <a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">dinutuximab</a> are administered concurrently. Holding lorlatinib during days of dinutuximab administration should be strongly considered for any patient with a prior history of significant lung dysfunction, prior sinusoidal obstruction syndrome (SOS), or recent/concurrent respiratory infections. Approximately 10 to 15 percent of patients with de novo high-risk neuroblastoma have activating mutations of the ALK receptor tyrosine kinase, and preclinical and early phase trials have demonstrated the safety and efficacy of ALK inhibition [<a href="#rid34">34,78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>MIBG therapy </strong>– Patients with MIBG avid disease enrolled in COG ANBL1531 are randomly assigned to receive I<sup>131</sup>-MIBG therapy between cycles 3 and 4 of induction or to receive standard therapy without I<sup>131</sup>-MIBG.</p><p></p><p class="bulletIndent1">While gamma emitting<sup> 123</sup>I-MIBG is effective as a highly specific functional imaging modality for neuroblastoma, the higher energy beta and gamma emitting<sup> 131</sup>I-MIBG is effective in the setting of relapsed disease and works via directed radiation-induced DNA damage [<a href="#rid79">79</a>]. MIBG therapy is effective against bone marrow and bony metastatic disease [<a href="#rid80">80</a>]. This supports a rationale for including MIBG therapy during induction to further decrease metastatic tumor burden during induction chemotherapy. Several phase I and II studies have demonstrated favorable response rates and toxicity profiles with this approach [<a href="#rid79">79,81,82</a>].</p><p></p><p class="headingAnchor" id="H293493238"><span class="h3">Local control</span><span class="headingEndMark"> — </span>As with other aggressive metastatic cancers, local control of the primary tumor plays an important role for high-risk neuroblastoma, and patients are treated with both surgery and radiation (administered after consolidation chemotherapy).</p><p class="headingAnchor" id="H3219693235"><span class="h4">Surgery</span><span class="headingEndMark"> — </span>The importance of achieving a gross total resection of the primary tumor in patients with disseminated disease is controversial, with some studies [<a href="#rid12">12,64,83-89</a>], but not others [<a href="#rid60">60,90,91</a>], suggesting a better outcome for complete resection. Surgical resection of the tumor should be performed by a pediatric surgeon with experience in resecting extensive, infiltrating tumors. Resection should be performed after several courses of induction chemotherapy, when the tumor is smaller and less invasive.</p><p class="headingAnchor" id="H2831003173"><span class="h4">Radiation therapy</span><span class="headingEndMark"> — </span>Radiation therapy (RT) to the primary tumor bed is recommended for high-risk neuroblastoma and is administered after consolidation therapy in most treatment protocols. RT is beneficial in preventing local tumor recurrence [<a href="#rid92">92-94</a>]. There is debate about whether the RT field should include lymph nodes adjacent to the primary tumor [<a href="#rid91">91,95</a>]. Similarly, there is discussion about which metastatic lesions need irradiation, and how this impacts local versus overall relapse risk [<a href="#rid96">96,97</a>]. For patients with residual tumor at the primary site after consolidation therapy, data are also conflicting for the efficacy of an additional radiation boost [<a href="#rid98">98,99</a>]. This approach is being investigated in a randomized SIOPEN trial, High-Risk Neuroblastoma Study 2 (HR-NBL2; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT04221035&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSwjDhjjcHHWHmVYzJmQHXMpRBf8eu1qhhNryBzcegLPWA%3D%3D&amp;TOPIC_ID=5203" target="_blank">NCT04221035</a>).</p><p class="headingAnchor" id="H2405326603"><span class="h3">Consolidation</span><span class="headingEndMark"> — </span>After tumor bulk has been decreased by chemotherapy and surgery, the consolidation phase includes high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation [<a href="#rid65">65,67,73,100,101</a>] and radiation therapy. Hematopoietic stem cells are collected using apheresis after the second cycle of induction chemotherapy. Although high-risk patients have bone marrow metastases at the time of diagnosis and may have residual disease in the bone marrow at the time of apheresis, the use of immunomagnetic "purging" of stem cell products [<a href="#rid67">67</a>] did not decrease the risk of recurrence or OS when evaluated in a prospective, randomized trial performed by the COG [<a href="#rid102">102</a>].</p><p>Consolidation therapy with hematopoietic stem cell rescue improves EFS but not OS, as demonstrated by a Cochrane review of three randomized trials conducted in 739 children with high-risk neuroblastoma [<a href="#rid103">103</a>]. In this analysis, compared with conventional treatment, high-dose chemotherapy and hematopoietic stem cell transplantation improved EFS (HR 0.79, 95% CI 0.70-0.90) and trended towards improved OS in two of the trials, although the results were not statistically significant (HR 0.86, 95% CI 0.73-1.01). There was no difference in secondary malignant disease and treatment-related death between the two treatment groups, although one of the trials showed a significantly higher rate of specific treatment-related toxicities in those treated with stem cell transplantation (eg, renal effects, interstitial pneumonitis and veno-occlusive disease) compared with those treated with conventional chemotherapy.</p><p class="headingAnchor" id="H1749073802"><span class="h4">Tandem transplants</span><span class="headingEndMark"> — </span>For patients with high-risk disease, tandem autologous hematopoietic stem-cell transplantation for consolidation has been shown to improve disease outcomes relative to single transplants.</p><p>In a multicenter COG study (ANBL0532), 355 patients with high-risk neuroblastoma were randomly assigned after induction therapy to either single transplant with carboplatin-etoposide-melphalan (CEM) or tandem (two) transplants with thiotepa-cyclophosphamide, followed by a modified CEM (TC:CEM) [<a href="#rid73">73</a>]. High-risk disease was defined as a tumor with amplification of t<em>he MYCN</em> oncogene occurring in children of any age; localized unresectable disease with unfavorable histology; or metastatic disease occurring in children who were older than 18 months at diagnosis. After a median follow-up of approximately five and a half years, while the tandem transplant group experienced improved three-year EFS compared with those receiving single transplants (61 versus 48 percent), the difference in OS at three years did not reach statistical significance (74 versus 69 percent). For the subset of patients receiving immunotherapy, tandem transplants were associated with improvements in both EFS (73 versus 55 percent) and OS (84 versus 74 percent). Cumulative rates of severe mucosal, infectious, or liver toxicities and regimen-related mortality were similar between arms. In addition, as dose intensity of treatment increases, the need to monitor for late effects including secondary cancers becomes even more important.</p><p>Based on these findings, this tandem transplant strategy is now incorporated into the COG trial ANBL1531 evaluating various induction strategies for patients with high-risk disease. (See <a class="local">'Induction'</a> above.)</p><p class="headingAnchor" id="H1268583193"><span class="h4">Investigational consolidation therapies</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative stem cell transplantation techniques</strong> <strong>(high-dose chemotherapy with </strong><a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a><strong> and </strong><a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a><strong>)</strong> – A randomized study suggests an advantage of high-dose chemotherapy with melphalan and busulfan over <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and melphalan (CEM) [<a href="#rid20">20</a>]. In a European phase III trial, approximately 600 patients with high-risk neuroblastoma that had responded to a multidrug induction regimen were randomly assigned to high-dose chemotherapy with either busulfan and melphalan or CEM, followed by autologous hematopoietic stem cell transplantation. Compared with patients treated with CEM, patients receiving busulfan plus melphalan had an improved three-year EFS (50 versus 38 percent) and five-year OS (54 versus 41 percent). Severe life-threatening toxicities occurred in 4 percent of patients receiving busulfan and melphalan versus 10 percent receiving CEM.</p><p></p><p class="bulletIndent1">High-dose chemotherapy with <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> and <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a> followed by one autologous hematopoietic stem cell transplant is being compared with tandem transplant in the COG trial ANBL1531 for patients with high-risk disease. (See <a class="local">'Induction'</a> above.)</p><p></p><p class="headingAnchor" id="H1912265102"><span class="h3">Maintenance</span><span class="headingEndMark"> — </span>Maintenance, the final phase of therapy, targets minimal residual disease. In this phase of therapy patients receive immunotherapy with an anti-GD2 monoclonal antibody and cis-retinoic acid, a differentiating biologic agent. There are multiple formulations of anti-GD2 monoclonal antibodies in use. However, specific agents that have been evaluated in randomized studies include <a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">dinutuximab</a> and dinutuximab beta. (See <a class="local">'Dinutuximab (preferred)'</a> below.)</p><p>Further maintenance therapy with eflornithine is an option after completion of maintenance immunotherapy with an anti-GD2 antibody. However, the clinical use of this agent is not standard across all institutions. Therefore, eflornithine may be offered based on institutional guidelines and on an individual patient basis. (See <a class="local">'Eflornithine'</a> below.)</p><p class="headingAnchor" id="H2617165889"><span class="h4">Dinutuximab (preferred)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">Dinutuximab</a> is approved by the US Food and Drug Administration (FDA) and has been evaluated in combination with granulocyte macrophage colony-stimulating factor (GM-CSF), interleukin 2 (IL-2), and cis-retinoic acid (<a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>) [<a href="#rid67">67,104</a>] for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior initial multimodality therapy.</p><p>Of note, available upfront trials in the United States and Europe no longer include IL-2 as part of standard consolidation, based on data from trials evaluating its use with dinutuximab-beta [<a href="#rid105">105,106</a>].</p><p><a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">Dinutuximab</a> (ch14.18) is a chimeric antibody that targets disialoganglioside GD2, a tumor-associated antigen uniformly expressed on neuroblastomas [<a href="#rid107">107,108</a>]. The addition of dinutuximab plus cytokines (GM-CSF and IL-2) was found to have benefit over cis-retinoic acid alone for prevention of recurrence in a randomized trial (ANBL0032) [<a href="#rid109">109</a>]. The immunotherapy approach resulted in superior two-year EFS (66 versus 46 percent) and OS rates (86 versus 75 percent). In extended follow-up of this study after cessation of random treatment assignment, patients treated with dinutuximab plus cytokines also demonstrated durable survival outcomes (five-year EFS and OS of 61 and 72 percent) [<a href="#rid110">110</a>]. Toxicities include serious and potentially life-threatening infusion reactions and severe neuropathic pain.</p><p class="headingAnchor" id="H1909269216"><span class="h4">Dinutuximab beta (alternative)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">Dinutuximab</a> beta is a separate anti-GD2 antibody currently used with a longer and slower dosing regimen than dinutuximab [<a href="#rid111">111</a>]. Dinutuximab beta has regulatory approval in Europe but not in the United States.</p><p><a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">Dinutuximab</a> beta may be administered without GM-CSF or cis-retinoic acid, although trials have typically included cis-retinoic acid [<a href="#rid105">105</a>]. In the International Society for Paediatric Oncology European Neuroblastoma (SIOPEN) trial, the addition of low-dose IL-2 to long-term infusion dinutuximab beta and cis-retinoic acid increased toxicity without improving outcomes [<a href="#rid105">105,106</a>].</p><p class="headingAnchor" id="H1486122696"><span class="h4">Eflornithine</span><span class="headingEndMark"> — </span>Eflornithine (ie, difluoromethylornithine [DFMO], an inhibitor of ornithine decarboxylase) is approved by the FDA as maintenance therapy in patients with high-risk neuroblastoma who achieve at least a partial response to prior systemic agents and have completed maintenance immunotherapy with an anti-GD2 antibody [<a href="#rid112">112</a>]. However, the clinical use of maintenance eflornithine is not standard across all institutions. Therefore, eflornithine may be offered based on institutional guidelines and on an individual patient basis. </p><p>Data supporting the use of eflornithine as maintenance therapy in high-risk neuroblastoma are as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>In a phase II trial of 81 patients with high-risk neuroblastoma treated with eflornithine as maintenance therapy after receiving standard induction and consolidation, five-year EFS and OS were 85 and 95 percent, respectively [<a href="#rid113">113,114</a>]. These values were higher than the five-year EFS and OS seen with historical controls (66 and 82 percent, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A separate analysis compared 92 patients with high-risk neuroblastoma who completed multimodality treatment ending with <a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">dinutuximab</a> followed by two years of maintenance eflornithine as part of one study (NMTRC003B) to 852 matched control patients with high-risk neuroblastoma who also completed multimodality treatment including maintenance dinutuximab as part of ANBL0032, but who did not receive eflornithine [<a href="#rid115">115</a>]. At median follow-up of up to 6.1 years, maintenance eflornithine after completion of immunotherapy was associated with improved EFS (HR 0.50, 95% CI, 0.29 to 0.84) and OS (HR, 0.38, 95% CI 0.19 to 0.76); these were further confirmed with propensity score–matched cohorts and sensitivity analyses.</p><p></p><p class="headingAnchor" id="H3516174507"><span class="h3">Other investigational approaches</span><span class="headingEndMark"> — </span>Despite intensive multimodality therapy, a common outcome of high-risk neuroblastoma is recurrence of disease followed by death [<a href="#rid2">2,9</a>]. Improving survival in this group of children is a priority in clinical trials conducted by international cooperative groups. Treatment options under investigation include maximizing the intensity of therapy with hematopoietic stem cell transplantation [<a href="#rid116">116-120</a>] and including anti-GD2 monoclonal antibodies to other phases of therapy for high-risk disease.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anti-GD2 monoclonal antibodies during induction</strong> –<strong> </strong>The anti-GD2 monoclonal antibody Hu14.18K322A is being investigated as a novel adjunct to induction chemotherapy. In an open label nonrandomized phase II trial (NB2012), 64 patients with high-risk neuroblastoma were treated with Hu14.18K322A coadministered with standard induction chemotherapy, followed by GM-CSF and low-dose IL-2 [<a href="#rid121">121,122</a>]. Subsequently, patients received consolidation chemotherapy with <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a> and <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> (with Hu14.18K322A administered when available) and maintenance therapy with Hu14.18K322A, GM-CSF, IL-2, and <a class="drug drug_general" data-topicid="8582" href="/z/d/drug information/8582.html" rel="external">isotretinoin</a>. After two cycles of induction chemotherapy, PR was seen in 42 patients (67 percent). Additionally, three-year EFS and OS were 74 and 86 percent, respectively, which is higher than what has been in observed in historical controls receiving similar chemotherapy without Hu14.18K322A (between 50 to 66 percent) [<a href="#rid74">74,109</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">Dinutuximab</a>, which has an established role in maintenance therapy, is also being evaluated as part of induction chemotherapy in another trial (ANBL17P1; <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03786783&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNszsXl23GjtgRPVEjzBVC70E9d4C72nyP%2BJlX9ya4ZCQ%3D%3D&amp;TOPIC_ID=5203" target="_blank">NCT03786783</a>). (See <a class="local">'Maintenance'</a> above.)</p><p></p><p class="headingAnchor" id="H3079772323"><span class="h2">Relapsed or refractory disease</span><span class="headingEndMark"> — </span>For patients with relapsed or refractory disease, we refer patients for clinical trials (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=5203" target="_blank">www.clinicaltrials.gov</a>), as standard treatment options are limited. These patients have usually received chemotherapy previously and have typically met the limit of dose intensity for young children. Standard treatment also confers multiple late effects including significant increased risk of secondary malignancy highlighting the need for new treatments that reduce toxicity and improve efficacy. (See <a class="local">'Long-term toxicities'</a> below.)</p><p>Approximately 20 percent of patients with high-risk neuroblastoma will have no/mixed response or progressive disease at the end of induction chemotherapy [<a href="#rid73">73,102</a>]. Furthermore, at least 40 percent of patients will experience disease recurrence after completing standard multimodal therapy [<a href="#rid123">123</a>]. While most relapses occur within the first two years after treatment completion, late relapse can occur as far out as 10 to 30 years after treatment completion [<a href="#rid124">124</a>]. These findings indicate the need to develop novel therapeutic concepts for neuroblastoma, data for which are discussed below. The safety, toxicities, and clinical efficacy of these approaches are an active area of clinical research.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Naxitamab</strong> – While the US Food and Drug Administration has approved the anti-GD2 monoclonal antibody <a class="drug drug_general" data-topicid="130243" href="/z/d/drug information/130243.html" rel="external">naxitamab</a> in combination with GM-CSF for select patients with relapsed and refractory neuroblastoma, there are limited published data regarding its efficacy, and it is not yet clear how to best incorporate this drug into clinical practice [<a href="#rid125">125</a>]. Per the FDA label, patients must have disease limited to the bone and/or bone marrow and must have demonstrated at least stable disease with their prior therapy [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dinutuximab</strong><strong> plus chemotherapy</strong> –<strong> </strong>The addition of <a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">dinutuximab</a> to chemotherapy in patients with relapsed or refractory disease shows high clinical response rates, including those previously receiving dinutuximab therapy [<a href="#rid126">126-128</a>].</p><p></p><p class="bulletIndent1">In a randomized COG trial ANBL1221 of 36 patients with neuroblastoma in first relapse/progression treated with <a class="drug drug_general" data-topicid="8573" href="/z/d/drug information/8573.html" rel="external">irinotecan</a> and <a class="drug drug_general" data-topicid="9699" href="/z/d/drug information/9699.html" rel="external">temozolomide</a>, the addition of <a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">dinutuximab</a> improved objective responses rates compared to <a class="drug drug_general" data-topicid="10344" href="/z/d/drug information/10344.html" rel="external">temsirolimus</a> (53 versus 6 percent) [<a href="#rid126">126</a>]. As a result of these initial data, additional patients were nonrandomly assigned to the dinutuximab arm, and included those who experienced disease relapse after (but not during) previous dinutuximab maintenance therapy [<a href="#rid127">127</a>]. Of the 53 total patients who received this therapy, objective responses were seen in 22 patients (42 percent), including 11 complete responses (21 percent), and 22 patients had stable disease (42 percent). However, total duration of response to this regimen could not be assessed because many patients went off study to receive other treatments, such as surgery or high-dose chemotherapy with autologous hematopoietic stem cell transplantation. This information was provided in a subsequent multicenter retrospective study of 146 patients with relapsed high-risk neuroblastoma who received dinutuximab with irinotecan and temozolomide, which showed a median progression-free survival of 13.1 months, with a median duration of response of 15.9 months [<a href="#rid128">128</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapy </strong>–<strong> </strong>There is interest in investigating immunotherapy approaches in patients with relapsed and refractory neuroblastoma. Such approaches include chimeric antigen receptor (CAR) expressing T cells [<a href="#rid129">129</a>], immune checkpoint inhibitors, vaccines [<a href="#rid130">130</a>], and antibodies that modulate the immune microenvironment. (See  <a class="medical medical_review" href="/z/d/html/99637.html" rel="external">"Principles of cancer immunotherapy"</a>.) </p><p></p><p class="bulletIndent1">In an open-label phase I/II trial, 27 patients with relapsed or refractory neuroblastoma were treated with GD2-CAR T cells expressing the inducible caspase 9 suicide gene (GD2-CART01) at a dose of 10 x 10<sup>6</sup> CAR-positive T cells per kg [<a href="#rid129">129</a>]. At median follow-up of 1.7 years, overall responses were seen in 17 patients (63 percent), including nine complete responses (33 percent) and eight partial responses (30 percent). Three-year OS and EFS rates were 60 and 36 percent, respectively. The rate of cytokine release syndrome was 74 percent but was mild in most patients. In one patient who developed an altered state of consciousness (later attributed to brain hemorrhage), the caspase 9 suicide gene was successfully activated via administration of rimiducid to rapidly remove GD2-CART01. (See  <a class="medical medical_review" href="/z/d/html/118012.html" rel="external">"Cytokine release syndrome (CRS)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Integration of cancer "omics"</strong> – Current methodologies permit global genomic characterization of neuroblastoma specific epigenetic, metabolic, transcriptional and translational oncogenic mechanisms [<a href="#rid131">131-133</a>]. This includes integration of genomic information retrieved at the single cell level. This work is revealing critical signaling networks, biomarkers, and novel therapeutic targets [<a href="#rid134">134-136</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Targeting</strong> <strong>tumor immune microenvironment and heterogeneity </strong>–<strong> </strong>Oncogenic functions in neuroblastoma modulate the tumor immune microenvironment, drive heterogeneity, and promote metastasis [<a href="#rid137">137-141</a>]. In addition, preclinical data suggest that neuroblastoma is a highly complex mixture of adrenergic and mesenchymal subtypes with different tumorigenic, metastatic, and regenerative potential [<a href="#rid142">142-145</a>] and inform ongoing translational research and trials.</p><p></p><p class="headingAnchor" id="H433139908"><span class="h1">MEDICAL COMPLICATIONS ASSOCIATED WITH NEUROBLASTOMA PRESENTATION</span></p><p class="headingAnchor" id="H24"><span class="h2">Spinal cord compression</span><span class="headingEndMark"> — </span>Between 5 and 15 percent of children with neuroblastoma present with spinal cord involvement. Spinal cord compression is considered an oncologic emergency. Prompt resolution is important to limit permanent neurologic impairment. (See  <a class="medical medical_review" href="/z/d/html/2820.html" rel="external">"Treatment and prognosis of neoplastic epidural spinal cord compression", section on 'Systemic therapy'</a>.)</p><p>In patients with neuroblastoma who present with spinal cord compression, most high-volume centers favor initial chemotherapy rather than surgical decompression due to the known risk of late spinal deformities in some children who undergo surgical treatment [<a href="#rid146">146</a>]. Radiation therapy (RT) is rarely used; tumors that progress on chemotherapy are normally treated with surgical decompression.</p><p>Neurologic recovery appears to be related to the severity of presenting neurologic deficits [<a href="#rid147">147-149</a>]. Up to 70 percent of patients with symptoms of cord compression at diagnosis may have residual long-term neurologic sequelae. Chemotherapy and laminectomy appear have equivalent outcomes, in terms of short- and long-term symptom relief, as well as overall survival (OS). Each therapeutic modality, however, carries inherent long- and short-term risks and should be determined on an individualized basis [<a href="#rid147">147,150</a>].</p><p class="headingAnchor" id="H25"><span class="h2">Opsoclonus myoclonus</span><span class="headingEndMark"> — </span>Neuroblastomas associated with the paraneoplastic opsoclonus-myoclonus-ataxia (OMA) syndrome only represent about 2 to 3 percent of all newly diagnosed neuroblastomas, and are usually of lower stage and have favorable prognosis for survival [<a href="#rid151">151,152</a>]. However, children with neuroblastoma and opsoclonus-myoclonus syndrome are often left with long-term neurologic deficits (eg, cognitive and motor delays, language deficits, and behavioral issues), indicating the necessity of prompt diagnosis and interventions [<a href="#rid151">151,153-156</a>]. (See  <a class="medical medical_review" href="/z/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma", section on 'Paraneoplastic syndromes'</a> and  <a class="medical medical_review" href="/z/d/html/15861.html" rel="external">"Opsoclonus-myoclonus-ataxia syndrome"</a>.)</p><p>Corticosteroids and intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIg) may improve long-term neurologic outcome for OMA [<a href="#rid151">151,156,157</a>]. Symptoms refractory to these treatments may respond to <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> immunosuppression, as well as corticotropin for neurologic symptoms [<a href="#rid158">158-160</a>]. In an open label randomized study of 53 patients with OMA and neuroblastoma treated with risk-based chemotherapy and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, the addition of IVIg improved OMA response rates (80 versus 40 percent) [<a href="#rid161">161</a>].</p><p class="headingAnchor" id="H3007302181"><span class="h2">Tumor lysis syndrome</span><span class="headingEndMark"> — </span>Patients with bulky or advanced stage disease may rarely be classified as being at intermediate risk for tumor lysis syndrome and may be offered prophylaxis against the complications of tumor lysis syndrome [<a href="#rid162">162</a>]. The treatment of tumor lysis syndrome is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/17050.html" rel="external">"Tumor lysis syndrome: Prevention and treatment"</a>.)</p><p class="headingAnchor" id="H26"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis for patients with neuroblastoma depends upon prognostic factors, risk stratification, extent and site of metastases, and treatment received. (See <a class="local">'Prognostic factors'</a> above and <a class="local">'Risk stratification'</a> above and <a class="local">'Treatment'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk disease</strong> – Patients with low-risk disease treated either with observation or surgical resection have event-free survival (EFS) rates of greater than 85 percent and OS approaching 100 percent [<a href="#rid39">39,40,44</a>]. (See <a class="local">'Low-risk disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate-risk disease</strong> –<strong> </strong>For patients with intermediate-risk disease, long-term survival rates are over 90 percent [<a href="#rid25">25,57</a>]. (See <a class="local">'Intermediate-risk disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk disease</strong> –<strong> </strong>Children with high-risk disease have long-term survival rates of approximately 50 percent, despite intensive multimodality strategies that include high-dose therapy with autologous hematopoietic stem cell rescue [<a href="#rid9">9,64</a>]. Prior to instituting these aggressive approaches, the long-term survival probability for children with high-risk disease was less than 15 percent. These patients should be encouraged to enroll in treatment protocols evaluating new therapies. (See <a class="local">'High-risk disease'</a> above.)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">LONG-TERM TOXICITIES</span><span class="headingEndMark"> — </span>Neuroblastoma survivors are at increased risk for long-term morbidity and mortality [<a href="#rid163">163-165</a>]. We recommend long-term follow-up that are consistent with childhood cancer survivorship guidelines from the Children's Oncology Group (COG) [<a href="#rid166">166</a>]. These patients should be followed by clinicians attuned to the special needs of this population. The frequency of surveillance varies depending upon extent of disease and level of exposure to radiation and chemotherapy [<a href="#rid167">167</a>]. (See  <a class="medical medical_review" href="/z/d/html/17015.html" rel="external">"Overview of cancer survivorship in adolescents and young adults"</a> and  <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers"</a>.)</p><p>In addition, there are several web-based patient portals that facilitate long-term access to patient treatment records and empower patients to seek long-term follow-up. Survivorship Care Plans (SCPs) are one important way to improve compliance and can ensure that adult survivors of pediatric cancer get critical follow-up care [<a href="#rid168">168-171</a>]. (See  <a class="medical medical_review" href="/z/d/html/17020.html" rel="external">"Assuring quality of care for cancer survivors: The survivorship care plan"</a>.)</p><p>Data have demonstrated increased risk of morbidity and mortality among childhood cancer survivors of neuroblastoma, which is likely related to disease and associated treatments [<a href="#rid163">163-165</a>]. As an example, the impact of treatment was demonstrated in one series of 954 neuroblastoma patients from the Childhood Cancer Survivor Study (CCSS) diagnosed between 1970 and 1986 who survived for at least five years [<a href="#rid163">163</a>]. This group had a significantly increased risk of overall mortality compared with the general population (standardized mortality ratio 5.6). The primary causes of death were recurrent disease and second malignancy. When compared with a cohort of siblings, the survivors' risk for chronic health conditions was also increased. The 20-year cumulative incidence of chronic health conditions was 41 percent, with most of these conditions involving the neurologic, sensory, endocrine, and musculoskeletal systems.</p><p>COG is enrolling patients in the Late Effects After High-Risk Neuroblastoma (LEAHRN) study (ALTE15N2, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT03057626&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSz9wsRalc77CFv9OFo%2BGIinA6RL1hx11uvaa8FRWh87SQ%3D%3D&amp;TOPIC_ID=5203" target="_blank">NCT03057626</a>). The goal of this study is to collect data about the long-term impact of neuroblastoma therapy on growth, organ function, neurocognitive function, and risk for second malignancy [<a href="#rid172">172</a>].</p><p>Examples of the mechanisms by which neuroblastoma or its treatment may affect survivors and associated surveillance recommendations include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary malignancies</strong> –<strong> </strong>One study demonstrated significant increases in subsequent malignant neoplasms (SMNs) in children treated with platinum agents and radiation-central components of high-risk neuroblastoma therapy [<a href="#rid173">173</a>]. These data are in addition to two studies of SMNs in neuroblastoma patient cohorts compared with untreated controls [<a href="#rid174">174,175</a>]. Secondary cancers include myeloid leukemias due to chemotherapy, as well as solid tumors, related to radiation therapy (RT). Of note, secondary hematopoietic malignancies are more common in the first five years off-therapy, while solid tumors predominate later [<a href="#rid174">174</a>]. Patients who received chemotherapy should be followed with complete blood counts, then bone marrow studies if abnormalities arise. Those treated with radiation should be followed with physical exams focusing on the radiation field. (See  <a class="medical medical_review" href="/z/d/html/4506.html" rel="external">"Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/16613.html" rel="external">"Overview of cancer survivorship care for primary care and oncology providers", section on 'Risk of subsequent primary cancer'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive deficits</strong> –<strong> </strong>Cognitive deficits in childhood cancer survivors are commonly attributed to cranial irradiation, either alone or as part of total-body irradiation (TBI), in very young children. Contemporary neuroblastoma treatment regimens rarely include cranial RT. Despite this, a Childhood Cancer Survivor Study (CCSS) has indicated that neuroblastoma survivors have increased risk for psychological impairment and increased need for special education resources compared with siblings [<a href="#rid176">176</a>]. This risk is present regardless of treatment modality. Neuroblastoma survivors would benefit from formal neurocognitive evaluation after completion of therapy, as well as follow-up of educational achievement through childhood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac toxicity</strong> –<strong> </strong>Anthracycline chemotherapy (eg, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>) can cause myocardial dysfunction and impaired myocardial growth. This risk is exacerbated in patients who require RT to fields that include the heart. One study identified cardiac dysfunction in over 20 percent of survivors of high-risk neuroblastoma [<a href="#rid177">177</a>]. Of note, current high-risk neuroblastoma protocols have fewer doxorubicin-containing cycles and have incorporated the use of the cardioprotectant agent <a class="drug drug_general" data-topicid="9338" href="/z/d/drug information/9338.html" rel="external">dexrazoxane</a>, which may decrease future cardiotoxicity [<a href="#rid73">73,102,178,179</a>]. (See  <a class="medical medical_review" href="/z/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a> and  <a class="medical medical_review" href="/z/d/html/17017.html" rel="external">"Cancer survivorship: Cardiovascular and respiratory issues"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sensorineural hearing loss</strong> –<strong> </strong>Hearing loss due to platinum chemotherapy is a common complication of treatment for high-risk neuroblastoma, occurring in as many as 82 percent of patients who have undergone high-dose chemotherapy with stem-cell rescue [<a href="#rid177">177,180-183</a>]. A full evaluation of hearing should be performed at the end of therapy, and patients should be followed with periodic audiograms thereafter. (See  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease</strong> –<strong> </strong>A number of neuroblastoma survivors have been noted to have decreased renal function [<a href="#rid182">182,183</a>]. Platinum drugs (<a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>) are known for nephrotoxicity. Additional renal damage may result from RT to the adrenal/abdominal primary tumor beds or from vascular injury at the time of tumor resection. For some patients with high-risk neuroblastoma, nephrectomy is necessary to obtain adequate tumor resection. In these circumstances, patients are left with single kidney physiology, placing them at risk for future renal failure. (See  <a class="medical medical_review" href="/z/d/html/7173.html" rel="external">"Overview of kidney disease in patients with cancer", section on 'Chronic kidney disease in patients with cancer'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrinopathies</strong> –<strong> </strong>Multiple endocrine effects are possible, including impaired linear growth, thyroid dysfunction, and incomplete puberty [<a href="#rid177">177,184,185</a>]. The growth and puberty issues appear to be largely due to RT (either abdominal RT or TBI) [<a href="#rid177">177</a>]. The thyroid dysfunction is associated with radioactive iodine in meta-iodobenzylguanidine (MIBG) therapy or scans [<a href="#rid177">177,185</a>]. (See  <a class="medical medical_review" href="/z/d/html/93313.html" rel="external">"Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scoliosis</strong> –<strong> </strong>Scoliosis may occur in a number of neuroblastoma survivors. Laminectomy, which may be required in the treatment of intraspinal tumor, increases the risk of scoliosis because of asymmetric growth of vertebral bodies [<a href="#rid146">146,147,186</a>]. In addition, RT involving the spine seems to have a dose-associated impact on the risk of developing scoliosis [<a href="#rid186">186</a>]. (See  <a class="medical medical_review" href="/z/d/html/91910.html" rel="external">"Scoliosis in the adult"</a>.)</p><p></p><p class="headingAnchor" id="H3367083563"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114548.html" rel="external">"Society guideline links: Neuroblastomas"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>–<strong> </strong>This topic is designed to be an overview for the general oncologist on the management of neuroblastoma. Patients should be managed in a clinical setting where appropriate expertise in the treatment of neuroblastoma is available.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>–<strong> </strong>Neuroblastomas are clinically heterogeneous tumors, varying in location, histopathologic appearance, and biologic characteristics. Neuroblastomas have a highly variable natural history, which can range from spontaneous regression, to maturation into benign ganglioneuroma, to aggressive disease with metastatic dissemination leading to death. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic factors </strong>– Key factors influencing the clinical behavior of neuroblastomas include tumor stage and prognostic factors (eg, patient age at diagnosis; pathologic risk classification; cytogenetics and molecular genetics). (See <a class="local">'Staging system'</a> above and <a class="local">'Prognostic factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment approach </strong>–<strong> </strong>The treatment of neuroblastoma is determined based on low-, intermediate-, and high-risk categories based on tumor stage and other clinical characteristics at diagnosis (including age and molecular/pathologic features). An updated risk classification system is available  (<a class="graphic graphic_figure graphicRef138386" href="/z/d/graphic/138386.html" rel="external">figure 1</a>) that is based on the INRGSS  (<a class="graphic graphic_table graphicRef88604" href="/z/d/graphic/88604.html" rel="external">table 1</a>). A previous risk classification schema  (<a class="graphic graphic_table graphicRef68159" href="/z/d/graphic/68159.html" rel="external">table 3</a>) was based on the INSS  (<a class="graphic graphic_table graphicRef73974" href="/z/d/graphic/73974.html" rel="external">table 2</a>). (See <a class="local">'Treatment'</a> above and <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-risk disease </strong>–<strong> </strong>For most children older than one year with low-risk disease (localized tumors without unfavorable characteristics), surgery alone is indicated. Patients treated with surgery typically do not require adjuvant chemotherapy. (See <a class="local">'Low-risk disease'</a> above and <a class="local">'Surgery (preferred for most patients with low-risk disease)'</a> above.)</p><p></p><p class="bulletIndent1">However, exceptions are made for the following patients with low-risk disease, given the high rate of spontaneous regression seen in such cases. (See <a class="local">'Subgroups that can be managed with observation alone'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For newborns and infants up to six months of age with small, asymptomatic L1 adrenal masses, we recommend observation (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>), forgoing diagnostic biopsy, and delaying therapy until the point of progression. (See <a class="local">'Newborns with small, asymptomatic adrenal masses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants with MS disease without hepatomegaly with tumors that are <em>MYCN</em> non-amplified, hyperdiploid, and favorable histology, we recommend observation (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>), delaying therapy until progression. (See <a class="local">'Infants with stage MS (4S) disease without hepatomegaly'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Some UpToDate experts also offer observation to select children less than one year old with asymptomatic, localized, biopsy-proven neuroblastoma with both favorable histology and genomics. However, this observational strategy is investigational, and other experts may alternatively offer standard treatment approaches (eg, surgery or chemotherapy) in these patients. (See <a class="local">'Infants less than one year old with localized disease &lt;5 cm'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intermediate-risk disease </strong>– For children with intermediate-risk disease, we suggest chemotherapy, with or without surgical resection, rather than upfront surgical resection (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Radiation therapy (RT) is rarely indicated. (See <a class="local">'Intermediate-risk disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High-risk disease</strong> – For children with high-risk disease, we recommend multimodality treatment rather than less aggressive treatment (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Multimodality treatment typically include induction chemotherapy, surgical resection, tandem autologous hematopoietic stem cell transplantation, and RT to the tumor bed and, potentially, metastatic sites, followed by maintenance with biologic/immunologic therapy (eg, <a class="drug drug_general" data-topicid="100325" href="/z/d/drug information/100325.html" rel="external">dinutuximab</a>). Extended maintenance therapy with eflornithine is an option, but its clinical use is not standard across all institutions. With this multimodality approach, long-term survival exceeds 50 percent, which compares favorably with survival rates of approximately 15 percent, prior to adoption of these strategies. (See <a class="local">'High-risk disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed and refractory disease </strong>– For patients with relapsed and refractory disease, standard treatment options are limited; we typically refer patients for clinical trials, where available. (See <a class="local">'Relapsed or refractory disease'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease complications</strong> – Neuroblastoma can be associated with certain medical complications including spinal cord compression, opsoclonus myoclonus, and, rarely, tumor lysis syndrome. (See <a class="local">'Medical complications associated with neuroblastoma presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– The prognosis for patients with neuroblastoma depends upon prognostic factors, risk stratification, extent and site of metastases, and treatment received. In general, the younger the age at diagnosis, the better the survival rate. One exception are newborns less than two months of age with stage MS neuroblastoma, who typically present with aggressive disease. (See <a class="local">'Prognosis'</a> above and <a class="local">'Newborns'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survivorship </strong>– Neuroblastoma survivors are at increased risk for long-term treatment-related toxicities, and treating clinicians should be aware of these potential challenges that face survivors and their families. We recommend long-term follow-up based on childhood cancer survivorship guidelines from the Children's Oncology Group (COG). (See <a class="local">'Long-term toxicities'</a> above.)</p><p></p><p class="headingAnchor" id="H3927359963"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Stefanie R Lowas, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith,MA, Gurney JG, et al (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.</li><li class="breakAll">Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Principles and Practice of Pediatric Oncology, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.886.</li><li><a class="nounderline abstract_t">Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466.</a></li><li><a class="nounderline abstract_t">Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009; 27:289.</a></li><li><a class="nounderline abstract_t">Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 2009; 27:298.</a></li><li><a class="nounderline abstract_t">Woods WG, LaQuaglia MP. The drama of the gifted disease. J Clin Oncol 2009; 27:172.</a></li><li><a class="nounderline abstract_t">Castleberry RP, Shuster JJ, Smith EI. The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group. J Clin Oncol 1994; 12:2378.</a></li><li><a class="nounderline abstract_t">Haase GM, Atkinson JB, Stram DO, et al. Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems. J Pediatr Surg 1995; 30:289.</a></li><li><a class="nounderline abstract_t">Coughlan D, Gianferante M, Lynch CF, et al. Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States. Pediatr Hematol Oncol 2017; 34:320.</a></li><li><a class="nounderline abstract_t">Evans AE, D'Angio GJ, Propert K, et al. Prognostic factor in neuroblastoma. Cancer 1987; 59:1853.</a></li><li><a class="nounderline abstract_t">DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol 1999; 21:181.</a></li><li><a class="nounderline abstract_t">Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol 1998; 16:1256.</a></li><li><a class="nounderline abstract_t">London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 2005; 23:6459.</a></li><li><a class="nounderline abstract_t">Morgenstern DA, Bagatell R, Cohn SL, et al. The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer 2019; 66:e27556.</a></li><li><a class="nounderline abstract_t">Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005; 23:6474.</a></li><li><a class="nounderline abstract_t">George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005; 23:6466.</a></li><li class="breakAll">SEER Cancer Statistics Review 1975-2016, Childhood Cancer section. Available at: https://seer.cancer.gov/csr/1975_2016/browse_csr.php?sectionSEL=28&amp;pageSEL=sect_28_table.08 (Accessed on January 02, 2020).</li><li><a class="nounderline abstract_t">Bender HG, Irwin MS, Hogarty MD, et al. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification. J Clin Oncol 2023; 41:3149.</a></li><li><a class="nounderline abstract_t">Friedman DN, Goodman PJ, Leisenring WM, et al. Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2023; 41:1565.</a></li><li><a class="nounderline abstract_t">Ladenstein R, Pötschger U, Pearson AD, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol 2017; 18:500.</a></li><li><a class="nounderline abstract_t">Mossé YP, Deyell RJ, Berthold F, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer 2014; 61:627.</a></li><li><a class="nounderline abstract_t">Gaspar N, Hartmann O, Munzer C, et al. Neuroblastoma in adolescents. Cancer 2003; 98:349.</a></li><li><a class="nounderline abstract_t">Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study. J Clin Oncol 1998; 16:2007.</a></li><li><a class="nounderline abstract_t">Nickerson HJ, Matthay KK, Seeger RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000; 18:477.</a></li><li><a class="nounderline abstract_t">Twist CJ, Naranjo A, Schmidt ML, et al. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol 2019; 37:115.</a></li><li><a class="nounderline abstract_t">D'Angio GJ, Evans AE, Koop CE. Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1971; 1:1046.</a></li><li><a class="nounderline abstract_t">Tas ML, Nagtegaal M, Kraal KCJM, et al. Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease. Pediatr Blood Cancer 2020; 67:e28061.</a></li><li><a class="nounderline abstract_t">Sokol E, Desai AV, Applebaum MA, et al. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. J Clin Oncol 2020; 38:1906.</a></li><li><a class="nounderline abstract_t">Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86:364.</a></li><li><a class="nounderline abstract_t">Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer 2001; 92:2451.</a></li><li><a class="nounderline abstract_t">Navarro S, Amann G, Beiske K, et al. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. J Clin Oncol 2006; 24:695.</a></li><li><a class="nounderline abstract_t">Shimada H, Chatten J, Newton WA Jr, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73:405.</a></li><li><a class="nounderline abstract_t">Irwin MS, Naranjo A, Zhang FF, et al. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol 2021; 39:3229.</a></li><li><a class="nounderline abstract_t">Bellini A, Pötschger U, Bernard V, et al. Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). J Clin Oncol 2021; 39:3377.</a></li><li><a class="nounderline abstract_t">Rosswog C, Fassunke J, Ernst A, et al. Genomic ALK alterations in primary and relapsed neuroblastoma. Br J Cancer 2023; 128:1559.</a></li><li><a class="nounderline abstract_t">Koneru B, Lopez G, Farooqi A, et al. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. Cancer Res 2020; 80:2663.</a></li><li><a class="nounderline abstract_t">Ackermann S, Cartolano M, Hero B, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. Science 2018; 362:1165.</a></li><li><a class="nounderline abstract_t">Attiyeh EF, London WB, Mossé YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353:2243.</a></li><li><a class="nounderline abstract_t">Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study. J Clin Oncol 2000; 18:18.</a></li><li><a class="nounderline abstract_t">Alvarado CS, London WB, Look AT, et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2000; 22:197.</a></li><li><a class="nounderline abstract_t">Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique. J Clin Oncol 1997; 15:1171.</a></li><li><a class="nounderline abstract_t">Bowman LC, Castleberry RP, Cantor A, et al. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst 1997; 89:373.</a></li><li><a class="nounderline abstract_t">De Bernardi B, Mosseri V, Rubie H, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br J Cancer 2008; 99:1027.</a></li><li><a class="nounderline abstract_t">Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol 2012; 30:1842.</a></li><li><a class="nounderline abstract_t">Interiano RB, Davidoff AM. Current Management of Neonatal Neuroblastoma. Curr Pediatr Rev 2015; 11:179.</a></li><li><a class="nounderline abstract_t">Acharya S, Jayabose S, Kogan SJ, et al. Prenatally diagnosed neuroblastoma. Cancer 1997; 80:304.</a></li><li><a class="nounderline abstract_t">Holgersen LO, Subramanian S, Kirpekar M, et al. Spontaneous resolution of antenatally diagnosed adrenal masses. J Pediatr Surg 1996; 31:153.</a></li><li><a class="nounderline abstract_t">Sauvat F, Sarnacki S, Brisse H, et al. Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study. Cancer 2002; 94:2474.</a></li><li><a class="nounderline abstract_t">Gigliotti AR, Di Cataldo A, Sorrentino S, et al. Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer 2009; 45:3220.</a></li><li><a class="nounderline abstract_t">Cañete A, Jovani C, Lopez A, et al. Surgical treatment for neuroblastoma: complications during 15 years' experience. J Pediatr Surg 1998; 33:1526.</a></li><li><a class="nounderline abstract_t">Yamamoto K, Hanada R, Kikuchi A, et al. Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 1998; 16:1265.</a></li><li><a class="nounderline abstract_t">Oue T, Inoue M, Yoneda A, et al. Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study. J Pediatr Surg 2005; 40:359.</a></li><li><a class="nounderline abstract_t">Tanaka M, Kigasawa H, Kato K, et al. A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening. Pediatr Blood Cancer 2010; 54:573.</a></li><li><a class="nounderline abstract_t">Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg 2012; 256:573.</a></li><li class="breakAll">National Institutes of Health (NIH) US National Library of Medicine ClinicalTrials.gov record for protocol ANBL1232. Available at: https://clinicaltrials.gov/ct2/show/NCT02176967 (Accessed on January 02, 2020).</li><li><a class="nounderline abstract_t">Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 2008; 26:1504.</a></li><li><a class="nounderline abstract_t">Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010; 363:1313.</a></li><li><a class="nounderline abstract_t">Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J Clin Oncol 2011; 29:449.</a></li><li><a class="nounderline abstract_t">Twist CJ, Schmidt ML, Naranjo A, et al. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol 2019; 37:3243.</a></li><li><a class="nounderline abstract_t">Strother D, van Hoff J, Rao PV, et al. Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group. Eur J Cancer 1997; 33:2121.</a></li><li><a class="nounderline abstract_t">Strother D, Shuster JJ, McWilliams N, et al. Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma. J Pediatr Hematol Oncol 1995; 17:254.</a></li><li><a class="nounderline abstract_t">Mullassery D, Farrelly P, Losty PD. Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis. Pediatr Hematol Oncol 2014; 31:703.</a></li><li><a class="nounderline abstract_t">Liang WH, Federico SM, London WB, et al. Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clin Cancer Inform 2020; 4:895.</a></li><li><a class="nounderline abstract_t">Fischer J, Pohl A, Volland R, et al. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC Cancer 2017; 17:520.</a></li><li><a class="nounderline abstract_t">Laprie A, Michon J, Hartmann O, et al. High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification. Cancer 2004; 101:1081.</a></li><li><a class="nounderline abstract_t">Pinto NR, Applebaum MA, Volchenboum SL, et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J Clin Oncol 2015; 33:3008.</a></li><li><a class="nounderline abstract_t">Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341:1165.</a></li><li><a class="nounderline abstract_t">Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005; 44:348.</a></li><li><a class="nounderline abstract_t">Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 2005; 6:649.</a></li><li><a class="nounderline abstract_t">Pinto N, Naranjo A, Hibbitts E, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer 2019; 112:66.</a></li><li><a class="nounderline abstract_t">Garaventa A, Poetschger U, Valteau-Couanet D, et al. Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. J Clin Oncol 2021; 39:2552.</a></li><li><a class="nounderline abstract_t">Berthold F, Faldum A, Ernst A, et al. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. Ann Oncol 2020; 31:422.</a></li><li><a class="nounderline abstract_t">Park JR, Kreissman SG, London WB, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA 2019; 322:746.</a></li><li><a class="nounderline abstract_t">Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol 2011; 29:4351.</a></li><li><a class="nounderline abstract_t">Granger MM, Naranjo A, Bagatell R, et al. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther 2021; 27:490.e1.</a></li><li><a class="nounderline abstract_t">Pearson AD, Pinkerton CR, Lewis IJ, et al. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 2008; 9:247.</a></li><li><a class="nounderline abstract_t">Ladenstein R, Valteau-Couanet D, Brock P, et al. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol 2010; 28:3516.</a></li><li><a class="nounderline abstract_t">Foster JH, Voss SD, Hall DC, et al. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res 2021; 27:3543.</a></li><li><a class="nounderline abstract_t">Kraal KC, Tytgat GA, van Eck-Smit BL, et al. Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan. Pediatr Blood Cancer 2015; 62:1886.</a></li><li><a class="nounderline abstract_t">Kayano D, Kinuya S. Current Consensus on I-131 MIBG Therapy. Nucl Med Mol Imaging 2018; 52:254.</a></li><li><a class="nounderline abstract_t">Kraal KC, Bleeker GM, van Eck-Smit BL, et al. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. Eur J Cancer 2017; 76:188.</a></li><li><a class="nounderline abstract_t">DuBois SG, Granger MM, Groshen S, et al. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol 2021; 39:3506.</a></li><li><a class="nounderline abstract_t">Haase GM, O'Leary MC, Ramsay NK, et al. Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma. J Pediatr Surg 1991; 26:1119.</a></li><li><a class="nounderline abstract_t">Chamberlain RS, Quinones R, Dinndorf P, et al. Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma. Ann Surg Oncol 1995; 2:93.</a></li><li><a class="nounderline abstract_t">McGregor LM, Rao BN, Davidoff AM, et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience. Cancer 2005; 104:2837.</a></li><li><a class="nounderline abstract_t">Zwaveling S, Tytgat GA, van der Zee DC, et al. Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may &gt;95 % tumour resection suffice? Pediatr Surg Int 2012; 28:953.</a></li><li><a class="nounderline abstract_t">von Allmen D, Davidoff AM, London WB, et al. Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. J Clin Oncol 2017; 35:208.</a></li><li><a class="nounderline abstract_t">Yang X, Chen J, Wang N, et al. Impact of extent of resection on survival in high-risk neuroblastoma: A systematic review and meta-analysis. J Pediatr Surg 2019; 54:1487.</a></li><li><a class="nounderline abstract_t">Holmes K, Pötschger U, Pearson ADJ, et al. Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study. J Clin Oncol 2020; 38:2902.</a></li><li><a class="nounderline abstract_t">Kiely EM. The surgical challenge of neuroblastoma. J Pediatr Surg 1994; 29:128.</a></li><li><a class="nounderline abstract_t">Simon T, Häberle B, Hero B, et al. Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis. J Clin Oncol 2013; 31:752.</a></li><li><a class="nounderline abstract_t">Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys 2003; 56:28.</a></li><li><a class="nounderline abstract_t">Marcus KJ, Shamberger R, Litman H, et al. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol 2003; 25:934.</a></li><li><a class="nounderline abstract_t">Pai Panandiker AS, Beltran C, Billups CA, et al. Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma. Pediatr Blood Cancer 2013; 60:761.</a></li><li><a class="nounderline abstract_t">Braunstein SE, London WB, Kreissman SG, et al. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer 2019; 66:e27736.</a></li><li><a class="nounderline abstract_t">Mazloom A, Louis CU, Nuchtern J, et al. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2014; 90:858.</a></li><li><a class="nounderline abstract_t">Polishchuk AL, Li R, Hill-Kayser C, et al. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2014; 89:839.</a></li><li><a class="nounderline abstract_t">Simon T, Hero B, Bongartz R, et al. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children &gt; 1 year with residual local disease. Strahlenther Onkol 2006; 182:389.</a></li><li><a class="nounderline abstract_t">Liu KX, Naranjo A, Zhang FF, et al. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol 2020; 38:2741.</a></li><li><a class="nounderline abstract_t">Berthold F, Ernst A, Hero B, et al. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. Br J Cancer 2018; 119:282.</a></li><li><a class="nounderline abstract_t">Jain R, Hans R, Totadri S, et al. Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations. Pediatr Blood Cancer 2020; 67:e28273.</a></li><li><a class="nounderline abstract_t">Kreissman SG, Seeger RC, Matthay KK, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 2013; 14:999.</a></li><li><a class="nounderline abstract_t">Yalçin B, Kremer LC, Caron HN, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev 2013; :CD006301.</a></li><li><a class="nounderline abstract_t">Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol 2009; 27:1007.</a></li><li><a class="nounderline abstract_t">Ladenstein R, Pötschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19:1617.</a></li><li><a class="nounderline abstract_t">Ladenstein RL, Poetschger U, Valteau-Couanet D, et al. Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial. J Clin Oncol 2019; 37S.</a></li><li><a class="nounderline abstract_t">Shusterman S, London WB, Gillies SD, et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 2010; 28:4969.</a></li><li><a class="nounderline abstract_t">Peinemann F, van Dalen EC, Enk H, Tytgat GA. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Database Syst Rev 2019; 4:CD012442.</a></li><li><a class="nounderline abstract_t">Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324.</a></li><li><a class="nounderline abstract_t">Desai AV, Gilman AL, Ozkaynak MF, et al. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol 2022; 40:4107.</a></li><li><a class="nounderline abstract_t">Flaadt T, Ladenstein RL, Ebinger M, et al. Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. J Clin Oncol 2023; 41:3135.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on January 30, 2024).</li><li><a class="nounderline abstract_t">Sholler GLS, Ferguson W, Bergendahl G, et al. Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep 2018; 8:14445.</a></li><li><a class="nounderline abstract_t">Lewis EC, Kraveka JM, Ferguson W, et al. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer 2020; 147:3152.</a></li><li><a class="nounderline abstract_t">Oesterheld J, Ferguson W, Kraveka JM, et al. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol 2024; 42:90.</a></li><li><a class="nounderline abstract_t">Pasqualini C, Dufour C, Goma G, et al. Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients. Bone Marrow Transplant 2016; 51:227.</a></li><li><a class="nounderline abstract_t">Grupp SA, Stern JW, Bunin N, et al. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 2000; 18:2567.</a></li><li><a class="nounderline abstract_t">Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 2002; 20:2284.</a></li><li><a class="nounderline abstract_t">von Allmen D, Grupp S, Diller L, et al. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J Pediatr Surg 2005; 40:936.</a></li><li><a class="nounderline abstract_t">George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 2006; 24:2891.</a></li><li><a class="nounderline abstract_t">Furman WL, Federico SM, McCarville MB, et al. A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clin Cancer Res 2019; 25:6320.</a></li><li><a class="nounderline abstract_t">Furman WL, McCarville B, Shulkin BL, et al. Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. J Clin Oncol 2022; 40:335.</a></li><li><a class="nounderline abstract_t">Berlanga P, Pasqualini C, Pötschger U, et al. Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience. Eur J Cancer 2021; 144:1.</a></li><li><a class="nounderline abstract_t">Milrod CJ, Binney G, Khan MA. Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma. Lancet Oncol 2023; 24:e519.</a></li><li class="breakAll">US Food and Drug Administration (FDA) label for naxitamab https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761171lbl.pdf (Accessed on November 30, 2020).</li><li><a class="nounderline abstract_t">Mody R, Naranjo A, Van Ryn C, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol 2017; 18:946.</a></li><li><a class="nounderline abstract_t">Mody R, Yu AL, Naranjo A, et al. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. J Clin Oncol 2020; 38:2160.</a></li><li><a class="nounderline abstract_t">Lerman BJ, Li Y, Carlowicz C, et al. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol 2023; 41:508.</a></li><li><a class="nounderline abstract_t">Del Bufalo F, De Angelis B, Caruana I, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. N Engl J Med 2023; 388:1284.</a></li><li><a class="nounderline abstract_t">Cheung IY, Cheung NV, Modak S, et al. Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression. J Clin Oncol 2021; 39:215.</a></li><li><a class="nounderline abstract_t">Boeva V, Louis-Brennetot C, Peltier A, et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet 2017; 49:1408.</a></li><li><a class="nounderline abstract_t">van Groningen T, Koster J, Valentijn LJ, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet 2017; 49:1261.</a></li><li><a class="nounderline abstract_t">Rajbhandari P, Lopez G, Capdevila C, et al. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. Cancer Discov 2018; 8:582.</a></li><li><a class="nounderline abstract_t">Speleman F, Park JR, Henderson TO. Neuroblastoma: A Tough Nut to Crack. Am Soc Clin Oncol Educ Book 2016; 35:e548.</a></li><li><a class="nounderline abstract_t">Zeka F, Decock A, Van Goethem A, et al. Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight 2018; 3.</a></li><li><a class="nounderline abstract_t">MacFarland S, Bagatell R. Advances in neuroblastoma therapy. Curr Opin Pediatr 2019; 31:14.</a></li><li><a class="nounderline abstract_t">Marrano P, Irwin MS, Thorner PS. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Genes Chromosomes Cancer 2017; 56:28.</a></li><li><a class="nounderline abstract_t">Kortlever RM, Sodir NM, Wilson CH, et al. Myc Cooperates with Ras by Programming Inflammation and Immune Suppression. Cell 2017; 171:1301.</a></li><li><a class="nounderline abstract_t">Zhang P, Wu X, Basu M, et al. MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database. Front Immunol 2017; 8:1473.</a></li><li><a class="nounderline abstract_t">Jabbari P, Hanaei S, Rezaei N. State of the art in immunotherapy of neuroblastoma. Immunotherapy 2019; 11:831.</a></li><li><a class="nounderline abstract_t">Cohen MA, Zhang S, Sengupta S, et al. Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras. Cell Stem Cell 2020; 26:579.</a></li><li><a class="nounderline abstract_t">Cariati F, Borrillo F, Shankar V, et al. Dissecting Intra-Tumor Heterogeneity by the Analysis of Copy Number Variations in Single Cells: The Neuroblastoma Case Study. Int J Mol Sci 2019; 20.</a></li><li><a class="nounderline abstract_t">Agarwal S, Lakoma A, Chen Z, et al. G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation. Cancer Res 2015; 75:2566.</a></li><li><a class="nounderline abstract_t">Hsu DM, Agarwal S, Benham A, et al. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res 2013; 73:4134.</a></li><li><a class="nounderline abstract_t">van Groningen T, Akogul N, Westerhout EM, et al. A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma. Nat Commun 2019; 10:1530.</a></li><li><a class="nounderline abstract_t">Yao KC, McGirt MJ, Chaichana KL, et al. Risk factors for progressive spinal deformity following resection of intramedullary spinal cord tumors in children: an analysis of 161 consecutive cases. J Neurosurg 2007; 107:463.</a></li><li><a class="nounderline abstract_t">Katzenstein HM, Kent PM, London WB, Cohn SL. Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience. J Clin Oncol 2001; 19:1047.</a></li><li><a class="nounderline abstract_t">De Bernardi B, Pianca C, Pistamiglio P, et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 2001; 19:183.</a></li><li><a class="nounderline abstract_t">Simon T, Niemann CA, Hero B, et al. Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma. Dev Med Child Neurol 2012; 54:347.</a></li><li><a class="nounderline abstract_t">Plantaz D, Rubie H, Michon J, et al. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology. Cancer 1996; 78:311.</a></li><li><a class="nounderline abstract_t">Russo C, Cohn SL, Petruzzi MJ, de Alarcon PA. Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 1997; 28:284.</a></li><li><a class="nounderline abstract_t">De Grandis E, Parodi S, Conte M, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009; 40:103.</a></li><li><a class="nounderline abstract_t">Telander RL, Smithson WA, Groover RV. Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma. J Pediatr Surg 1989; 24:11.</a></li><li><a class="nounderline abstract_t">Koh PS, Raffensperger JG, Berry S, et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994; 125:712.</a></li><li><a class="nounderline abstract_t">Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol 2002; 38:229.</a></li><li><a class="nounderline abstract_t">Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study. Med Pediatr Oncol 2001; 36:612.</a></li><li><a class="nounderline abstract_t">Petruzzi MJ, de Alarcon PA. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 1995; 127:328.</a></li><li><a class="nounderline abstract_t">Battaglia T, De Grandis E, Mirabelli-Badenier M, et al. Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments. Eur J Paediatr Neurol 2012; 16:192.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED, Verhulst SJ, et al. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2010; 32:e167.</a></li><li><a class="nounderline abstract_t">Pranzatelli MR, Tate ED, McGee NR, MacArthur CA. Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome. Pediatr Neurol 2018; 85:71.</a></li><li><a class="nounderline abstract_t">de Alarcon PA, Matthay KK, London WB, et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health 2018; 2:25.</a></li><li><a class="nounderline abstract_t">Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010; 149:578.</a></li><li><a class="nounderline abstract_t">Laverdière C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009; 101:1131.</a></li><li><a class="nounderline abstract_t">Wilson CL, Brinkman TM, Cook C, et al. Clinically ascertained health outcomes, quality of life, and social attainment among adult survivors of neuroblastoma: A report from the St. Jude Lifetime Cohort. Cancer 2020; 126:1330.</a></li><li><a class="nounderline abstract_t">Haghiri S, Fayech C, Mansouri I, et al. Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue. Bone Marrow Transplant 2021; 56:1984.</a></li><li class="breakAll">Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, version 5.0 (October 2018), available online at http://www.survivorshipguidelines.org/ (Accessed on February 10, 2022).</li><li><a class="nounderline abstract_t">Friedman DN, Henderson TO. Late Effects and Survivorship Issues in Patients with Neuroblastoma. Children (Basel) 2018; 5.</a></li><li><a class="nounderline abstract_t">Pannier ST, Mann K, Warner EL, et al. Survivorship care plan experiences among childhood acute lymphoblastic leukemia patients and their families. BMC Pediatr 2019; 19:111.</a></li><li><a class="nounderline abstract_t">Petersson-Ahrholt M, Wiebe T, Hjorth L, et al. Development and Implementation of Survivorship Tools to Enable Medical Follow-Up After Childhood Cancer Treatment in Southern Sweden. JCO Clin Cancer Inform 2019; 3:1.</a></li><li class="breakAll">Gramatges MM, de Nigris FB, King J, et al. Improving childhood cancer survivor care through web-based platforms. Cancernetwork.com, vol 32, January 15, 2018. Available at: https://www.cancernetwork.com/pediatric-cancers/improving-childhood-cancer-survivor-care-through-web-based-platforms (Accessed on January 03, 2020).</li><li><a class="nounderline abstract_t">Kadan-Lottick NS, Ross WL, Mitchell HR, et al. Randomized Trial of the Impact of Empowering Childhood Cancer Survivors With Survivorship Care Plans. J Natl Cancer Inst 2018; 110:1352.</a></li><li class="breakAll">National Institutes of Health (NIH) US National Library of Medicine ClinicalTrials.gov record for protocol ALTE15N2. Available at: https://clinicaltrials.gov/ct2/show/NCT03057626 (Accessed on January 03, 2020).</li><li><a class="nounderline abstract_t">Turcotte LM, Liu Q, Yasui Y, et al. Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort. J Clin Oncol 2019; 37:3310.</a></li><li><a class="nounderline abstract_t">Applebaum MA, Vaksman Z, Lee SM, et al. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2017; 72:177.</a></li><li><a class="nounderline abstract_t">Applebaum MA, Henderson TO, Lee SM, et al. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer 2015; 62:128.</a></li><li><a class="nounderline abstract_t">Zheng DJ, Krull KR, Chen Y, et al. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study. Cancer 2018; 124:3220.</a></li><li><a class="nounderline abstract_t">Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems. Bone Marrow Transplant 2014; 49:502.</a></li><li class="breakAll">National Institutes of Health (NIH) US National Library of Medicine ClinicalTrials.gov record for protocol ANBL1531. Available at: https://clinicaltrials.gov/ct2/show/NCT03126916 (Accessed on January 03, 2020).</li><li class="breakAll">National Institutes of Health (NIH) US National Library of Medicine ClinicalTrials.gov record for protocol ANBL17P1. Available at: https://clinicaltrials.gov/ct2/show/NCT03786783 (Accessed on January 03, 2020).</li><li><a class="nounderline abstract_t">Simon T, Hero B, Dupuis W, et al. The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr 2002; 214:149.</a></li><li><a class="nounderline abstract_t">Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group. J Clin Oncol 2014; 32:527.</a></li><li><a class="nounderline abstract_t">Moreno L, Vaidya SJ, Pinkerton CR, et al. Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience. Pediatr Blood Cancer 2013; 60:1135.</a></li><li><a class="nounderline abstract_t">Perwein T, Lackner H, Sovinz P, et al. Survival and late effects in children with stage 4 neuroblastoma. Pediatr Blood Cancer 2011; 57:629.</a></li><li><a class="nounderline abstract_t">van Santen HM, de Kraker J, van Eck BL, et al. High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma. Cancer 2002; 94:2081.</a></li><li><a class="nounderline abstract_t">van Santen HM, de Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005; 41:1767.</a></li><li><a class="nounderline abstract_t">Paulino AC, Fowler BZ. Risk factors for scoliosis in children with neuroblastoma. Int J Radiat Oncol Biol Phys 2005; 61:865.</a></li></ol></div><div id="topicVersionRevision">Topic 5203 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Goodman MT, Gurney JG, Smith MA, Olshan AF. Sympathetic nervous system tumors. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program, 1975-1995, Ries LA, Smith,MA, Gurney JG, et al (Eds), National Cancer Institute, Bethesda, MD 1999. p.35.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Principles and Practice of Pediatric Oncology, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.886.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8336186" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047291" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047290" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19047304" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The drama of the gifted disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7964953" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The Pediatric Oncology Group experience with the international staging system criteria for neuroblastoma. Member Institutions of the Pediatric Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7738753" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Surgical management and outcome of locoregional neuroblastoma: comparison of the Childrens Cancer Group and the international staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29039999" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3567848" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prognostic factor in neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10363850" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552023" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116153" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30479064" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The challenge of defining "ultra-high-risk" neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116154" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116152" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116152" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37098238" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36525618" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-Term Morbidity and Mortality Among Survivors of Neuroblastoma Diagnosed During Infancy: A Report From the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28259608" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24038992" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12872356" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neuroblastoma in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626197" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10653863" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30444686" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4102970" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Special pattern of widespread neuroblastoma with a favourable prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31736229" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32315273" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10421273" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The International Neuroblastoma Pathology Classification (the Shimada system).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11745303" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16446343" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6589432" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34319759" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34115544" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36807339" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Genomic ALK alterations in primary and relapsed neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32291317" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30523111" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A mechanistic classification of clinical phenotypes in neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16306521" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Chromosome 1p and 11q deletions and outcome in neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10623689" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10864050" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060561" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the SociétéFrancaise d'Oncologie Pédiatrique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060959" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18766186" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22529259" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26168943" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Current Management of Neonatal Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217044" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Prenatally diagnosed neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8632270" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Spontaneous resolution of antenatally diagnosed adrenal masses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12015773" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outcome of suprarenal localized masses diagnosed during the perinatal period: a retrospective multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19767197" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9802806" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Surgical treatment for neuroblastoma: complications during 15 years' experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9552024" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Spontaneous regression of localized neuroblastoma detected by mass screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750929" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20049932" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A prospective study of a long-term follow-up of an observation program for neuroblastoma detected by mass screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22964741" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22964741" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349403" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20879880" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21172879" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31386611" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9516866" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7620924" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Results of pediatric oncology group protocol 8104 for infants with stages D and DS neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25247398" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Does aggressive surgical resection improve survival in advanced stage 3 and 4 neuroblastoma? A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058692" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28778185" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15329919" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : High-dose chemotherapy followed by locoregional irradiation improves the outcome of patients with international neuroblastoma staging system Stage II and III neuroblastoma with MYCN amplification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304901" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Advances in Risk Classification and Treatment Strategies for Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10519894" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15546135" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16129365" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30947024" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34152804" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32067684" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31454045" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010014" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33823167" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18308250" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20567002" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33568345" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25981988" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Upfront treatment of high-risk neuroblastoma with a combination of 131I-MIBG and topotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30100938" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Current Consensus on I-131 MIBG Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329731" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34270348" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1941492" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Aggressive surgery combined with intensive chemotherapy improves survival in poor-risk neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7728576" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Complete surgical resection combined with aggressive adjuvant chemotherapy and bone marrow transplantation prolongs survival in children with advanced neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16288490" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22722825" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may&gt;95 % tumour resection suffice?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27870572" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30262202" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Impact of extent of resection on survival in high-risk neuroblastoma: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639845" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8176583" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The surgical challenge of neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23284039" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694821" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14663275" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23024112" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Intensity modulated radiation therapy provides excellent local control in high-risk abdominal neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30968542" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25245583" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24867534" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16826357" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children&gt;1 year with residual local disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32530765" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29991700" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32196923" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Autologous stem cell transplant for high-risk neuroblastoma: Achieving cure with low-cost adaptations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23890779" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23970444" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171716" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442501" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Randomization of dose-reduced subcutaneous interleukin-2 (scIL2) in maintenance immunotherapy (IT) with anti-GD2 antibody dinutuximab beta (DB) long-term infusion (LTI) in front–line high-risk neuroblastoma patients: Early results from the HR-NBL1/SIOPEN trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20921469" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31016728" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20879881" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35839426" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36854071" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36854071" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30262852" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Maintenance DFMO Increases Survival in High Risk Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32391579" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37883734" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26524264" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Tandem high-dose chemotherapy with thiotepa and busulfan-melphalan and autologous stem cell transplantation in very high-risk neuroblastoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893288" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11980999" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15991174" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16782928" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31601569" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34871104" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33316634" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Central nervous system relapse in high-risk stage 4 neuroblastoma: The HR-NBL1/SIOPEN trial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38040004" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38040004" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28549783" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32343642" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36206505" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37018492" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33326254" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28740262" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28650485" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Neuroblastoma is composed of two super-enhancer-associated differentiation states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29510988" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27249766" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Neuroblastoma: A Tough Nut to Crack.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30518699" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30480556" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Advances in neuroblastoma therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27465929" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29195074" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29163537" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31094257" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : State of the art in immunotherapy of neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32142683" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Formation of Human Neuroblastoma in Mouse-Human Neural Crest Chimeras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30791380" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Dissecting Intra-Tumor Heterogeneity by the Analysis of Copy Number Variations in Single Cells: The Neuroblastoma Case Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25908586" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : G-CSF Promotes Neuroblastoma Tumorigenicity and Metastasis via STAT3-Dependent Cancer Stem Cell Activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687340" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30948783" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : A NOTCH feed-forward loop drives reprogramming from adrenergic to mesenchymal state in neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18154014" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Risk factors for progressive spinal deformity following resection of intramedullary spinal cord tumors in children: an analysis of 161 consecutive cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181668" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Treatment and outcome of 83 children with intraspinal neuroblastoma: the Pediatric Oncology Group experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11134211" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22329756" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8674009" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078325" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20020394" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2723981" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Clinical outcome in children with acute cerebellar encephalopathy and neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7525913" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920786" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344492" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children's Cancer Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7636667" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21737325" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20606544" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30197220" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Evaluation of Responsiveness to Reduced-Dose Rituximab in Corticotropin/Intravenous Immunoglobulin/Rituximab Combination Immunotherapy for Opsoclonus-Myoclonus Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29376112" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20331465" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19648511" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31923330" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Clinically ascertained health outcomes, quality of life, and social attainment among adult survivors of neuroblastoma: A report from the St. Jude Lifetime Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33824435" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33824435" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30082653" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Late Effects and Survivorship Issues in Patients with Neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30979365" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Survivorship care plan experiences among childhood acute lymphoblastic leukemia patients and their families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31173516" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Development and Implementation of Survivorship Tools to Enable Medical Follow-Up After Childhood Cancer Treatment in Southern Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31173516" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Development and Implementation of Survivorship Tools to Enable Medical Follow-Up After Childhood Cancer Treatment in Southern Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771337" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Randomized Trial of the Impact of Empowering Childhood Cancer Survivors With Survivorship Care Plans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29771337" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Randomized Trial of the Impact of Empowering Childhood Cancer Survivors With Survivorship Care Plans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31622130" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28033528" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25251613" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Second malignancies in patients with neuroblastoma: the effects of risk-based therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29888538" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24442245" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24442245" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24442245" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: high incidence of endocrine and growth problems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12165893" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : The incidence of hearing impairment after successful treatment of neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419114" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23281263" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Long-term follow-up of children with high-risk neuroblastoma: the ENSG5 trial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21319289" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Survival and late effects in children with stage 4 neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11932913" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : High incidence of thyroid dysfunction despite prophylaxis with potassium iodide during (131)I-meta-iodobenzylguanidine treatment in children with neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16039114" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Endocrine late effects from multi-modality treatment of neuroblastoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708267" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Risk factors for scoliosis in children with neuroblastoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
